

1. Bhatia S, Robison L, Oberlin O et al. (1996): Breast cancer and other second neoplasms after childhood Hodgkin's disease. *New Eng J Med* 334: 745.
2. Bos JL (1989): ras oncogene in human cancer: a review. *Cancer Res* 49: 4682.
3. Comings DE (1973): A general theory of carcinogenesis. *PNAS* 70: 3324.
4. Donehower LA and Bradley A (1993): The tumor suppressor p53. *Bioch Bio-phys Acta* 1155: 181.
5. Ewing J (1919): Neoplastic diseases. A textbook on tumors. Philadelphia, Paris: W. B. Saunders Co. pp 473, 494, 495.
6. Farrar W, Walker M and Minton J (1995): Physiology of the breast. In: *Cancer of the Breast*. Donegan and Spratt (eds). W. B. Saunders Company 43.
7. Fletcher GH (1976): Reflection on breast cancer. *Int Radiat Oncol Biol Phys* 1769.
8. Folkman J (1994): Tumor angiogenesis. In: *The molecular basis of cancer*. Mendelsohn, Howley, Liotta, Israel (eds.), W. B. Saunders Company, USA, 1995.
9. Fox T (1965): The purpose of medicine: the Harveian Oration. *Lancet*. ii: 801.
10. Frantz AG and Wilson JD (1985): Endocrine disorders of the breast In: *Wilson JD and Fuster DW (eds). Williams Textbook of Endocrinology*. W. B. Saunders Company. USA 402.
11. Haagensen C (1981): *Breast Carcinoma, Risk and Detection*, Saunders Company.
12. Haagensen CD (1986): *Diseases of the breast*, Ed. 3, Philadelphia, W. B. Saunders,
13. Harris JR, Lippman ME, Morrow M, Osborne CK (2000): *Diseases of the Breast*. Lippincott Williams & Wilkins. 2nd Ed. Philadelphia.
14. Harris JR, Morrow M and Bonadonna G (1993): *Cancer in the breast, from Cancer Principles and Practice of Oncology*, Fourth edition, edited by DeVita VT Jr, Helman S and Rosenberg JB, Lippincott Co., Philadelphia.
15. Haves DF (2000): Evaluation of patients after primary therapy. In Harris JR, Lippman ME, Morrow M, Osborne C K. Eds. *Diseases of the breast*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, pp 709.
16. Henderson IC and Canellos GP (1980): Cancer of the breast: The past decade. *New Eng. J. Med.* 302: 78.
17. Hynes NE and Stern DF (1994): The biology of erbB-2/neu/HER-2 and its role in cancer. *Bioch Bioph Acta J* 1198:165.

18. Keller-Wood M and Bland KI (1991): Breast physiology. In: The breast, comprehensive management of benign and malignant disease. Bland and Co-peland (eds). W. B. Saunders, USA: 37.
19. Leis HPJ (1978): The Breast. The CV Mosby Co. Saint Louis.
20. McDivitt RW (1978): Breast carcinoma. Hum. Pathol 9: 3
21. Nesland JM, Halm R. and Johannessen JV (1986): Neuroendocrine differentiation in breast lesions. Pathol Res Pract 181: 524.
22. Savitsky K, Bar-Shira A, Gilad S et al. (1995): A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268: 1749.
23. Urban J (1981): Surgical Treatment of Primary Breast Cancer, Edited Lewison E, Montague A. Conservative versus radical Diagnosis and Treatment of Breast Cancer. Williams and Wilkins, Baltimore, London.
24. Vashst A, Studd JWW (2000) Molecular mechanism of estrogen- the gynecologist's viewpoint. Eur J Cancer 36 (suppl 4) S 14-S 15
25. Vergote I, Neven P, van Dam P, Serreyn R, De Prins F, De Sutter Ph, Albertyn G (2000): The estrogen receptor and its selective modulators in gynecological and breast cancer. Eur J Cancer 36 (S1-S9).

Epidemiology, Risk factors Genetic predisposition Prevention

26. Anderson DE, Badzioch MD (1985): Risk of familial breast cancer. Cancer 56: 383-7.
27. Antoniou, A.C. Sinilnikova O.M, Simard J, et al. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81, 1186-200 (2007).
28. Armstrong MD, Eisen A, Weber B (2000): Assessing the risk of breast cancer. N Engl J Med 342:564-71.
29. Armstrong, K., Schwartz, J.S., Randall, T., Rubin, S.C. & Weber, B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 22, 1045-54 (2004).
30. Bernstein L, Henderson B, Hanisch R et al. (1994): Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 86: 1403

31. Bieseck B, Boehnke M, Calzone K et al. (1993): Genetic counseling for families with inherited susceptibility of breast and ovarian cancer. *JAMA* 269: 1970.
32. Boulton, S.J. Cellular functions of the BRCA tumour-suppressor proteins. *Biochem Soc Trans* 34, 633-45 (2006).
33. Brekelmans CTM, Seynaeve C, Bartels CCM et al. (2001): Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. *J Clin Oncol* 19, 924-30 (2001).
34. Castilla L, Couch F, Erdos M et al. (1994): Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. *Nature Genet* 8: 387.
35. Chen Y, Farmer A, Chen C-F et al. (1996): BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependant manner. *Cancer Res.* 56: 3168.
36. Cheng L, Hansen M and Strong L (1994): Genetic epidemiologic methods in risk determination in Li-Fraumeni syndrome families. *Am J Hum Genet suppl* 5: abstract No. 853.
37. Claus E, Risch N and Thompson W (1991): Genetic analysis of breast cancer in the cancer and steroid hormone study. *Am J Hum Genet* 48: 232.
38. Claus EB, Risch N, Thompson WD (1994): Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. *Cancer*, 73:643-51.
39. Chapman M and Verma I (1996): Transcriptional activation by BRCA1. *Nature* 382: 678.
40. Chen Y, Chen C-F, Riley D et al. (1995): Aberrant subcellular localization of BRCA1 in breast cancer. *Science* 270: 789.
41. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. *Am J Hum Genet* 74, 1175-82 (2004).
42. Coleman MP, Sloggett A, Babb P et al. (2000): Trends in breast cancer incidence, survival and mortality. *Lancet* 356:590-91.
43. Collins N, McManus R, Wooster R et al. (1995): Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. *Oncogene* 10: 1673-5.
44. Comings, D.E. A general theory of carcinogenesis. *Proc Natl Acad Sci U S A* 70, 3324-8 (1973).
45. Cox, A. et al. A common coding variant in CASP8 is associated with breast cancer risk. *Nat Genet* 39, 352-8 (2007).
46. Cuzick, J. et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. *Lancet* 360, 817-24 (2002).

42. Dong, L.M. et al. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. *Jama* 299, 2423-36 (2008).
47. Easton D (1994): Cancer risks in A-T heterozygotes. *Int. J Radiat Biol* 66: 177.
48. Easton, D.F., Narod, S.A., Ford, D. & Steel, M. The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium. *Lancet* 344, 761 (1994).
49. Easton, D.F. How many more breast cancer predisposition genes are there? *Breast Cancer Res* 1, 14-7 (1999).
50. Easton, D.F. Deffenbaugh A.M., Pruss D et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. *Am J Hum Genet* 81, 873-83 (2007).
51. Easton D, Ford D, Bishop T and the Breast Cancer Linkage Consortium (1995): Breast and ovarian cancer incidence in BRCA1 mutation carriers. *Am J Hum Genet* 56: 265.
52. Eisen, A. et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. *J Clin Oncol* 23, 7491-6 (2005).
53. Eisinger, F. et al. [Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004)]. *Bull Cancer* 91, 219-37 (2004).
54. Ewertz M, Duffy S, Adami HO et al. (1990) Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from Nordic countries. *Int J Cancer* 46:597- 603.
55. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. *Lancet* 358, 1389-99 (2001).
56. Fisher, B. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst* 97, 1652-62 (2005).
57. Fitzgerald M, Macdonald D, Krainer M et al. (1996): Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. *New Eng J Med* 334: 143.
58. Ford D, Easton DF, Bishop DT et al. (1994): Risks of cancer in BRCA1 mutation carriers. *Lancet* 343: 692.
59. Ford D, Easton DF, Stratton M, S. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet* 62, 676-89 (1998).
60. Forssen UM, Feychting M, Rutqvist LE, et al. (2000): Occupational and residential magnetic field exposure and breast cancer in females. *Epidemiol* 11:24-29

61. Foster K, Harrington P, Kerr J et al. (1996): Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. *Cancer Res.* 56: 3622.
62. Friedman L, Ostermeier E, Szabo C et al. (1994): Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. *Nature Genet* 8: 399.
63. Futreal P, Liu, Q, Shattuck-Eidens D et al. BRCA1 mutations in primary breast and ovarian carcinomas. *Science* 266: 120. (1994):
64. Gail, M.H. Brinton, LA Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. *J Natl Cancer Inst* 81, 1879-86 (1989).
65. Ghadidan P, Narod S, Perret S et al. (1995): Hereditary breast cancer in 19 females and 2 males: Kindred PG 1940. *Eur J Cancer* 31A: 284.
66. Gronwald, J. Tung N, Foulkes WD et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. *Int J Cancer* 118, 2281-4 (2006).
67. Hall, J.M. et al. Linkage of early-onset familial breast cancer to chromosome 17q21. *Science* 250, 1684-9 (1990).
68. Hartmann, L.C. et Schaid DJ, Ph.D., Woods JE , al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. *N Engl J Med* 340, 77-84 (1999).
61. Hartmann, L.C. et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. *J Natl Cancer Inst* 93, 1633-7 (2001).
62. Hirsch, B. Shimamura A, Moreau L, et al. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. *Blood* 103, 2554-9 (2004).
63. Sorlie, T. Tibshirani R, Parker J, et al. Repeated observation of breast tumor sub-types in independent gene expression data sets. *Proc Natl Acad Sci U S A* 100, 8418-23 (2003).
69. Honrado, E., Benitez, J. & Palacios, J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. *Mod Pathol* 18, 1305-20 (2005).
70. Howe G, Hirohata T, Hislop T et al. (1990): Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. *J. Natl. Cancer Inst.* 82: 561.
71. Humphrey, L.L., Helfand, M., Chan, B.K. & Woolf, S.H. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 137, 347-60 (2002).
72. Hunter DJ, Spiegelman D, Adami HO, et al. (1996): Cohort studies of fat intake and the risk of breast cancer - a pooled analysis. *N Engl J Med* 334:356-61.

73. Hunter DJ, Spiegelman D, Adami HO et al. (1997): Non-dietary factors as risk factors for breast cancer, and as effect modifiers of the association of fat intake and risk of breast cancer. *Cancer Causes Control* 8:49-56.
74. Hunter DJ, Willett WC (1993): Diet, body size, and breast cancer. *Epidemiol Rev* 15:11-32
75. Jakubowska, A. et al. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers. *Cancer Epidemiol Biomarkers Prev* 16, 270-5 (2007).
76. Jemal A., Ward E., Thun M.J. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women *Breast Cancer Res* 2007, 9 3 R28
77. John E.M. Miron A, Gong G; et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. *Jama* 298, 2869-76 (2007).
78. Johson H., Johansson R., Lenner P. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. *Int J cancer* 2005, 117: 842-7. Kauff, N.D. et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 346, 1609-15 (2002).
79. Kerangueven F, Essioux L, Dib A et al. (1990): Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. *Oncogene* 10: 1023.
80. Key TJ, Verkasalo PK (1999): Endogenous hormones and etiology of breast cancer. *Breast Cancer Res*, (<http://breast-cancer-research.com>) 1(1): editoral/2
81. Knudson, A.G., Jr. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A* 68, 820-3 (1971).
82. Kriege, M. Brekelmans C TM, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. *N Engl J Med* 351, 427-37 (2004).
83. Kroiss, R. et al. Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers. *Hum Mutat* 26, 583-9 (2005).
84. Krontiris T, Devlin B, Karp D et al. (1993): An association between the risk of cancer and mutations in the H-ras 1 minisatellite locus. *New Engl J Med* 329: 517.
85. Krontiris T, Di Martino N, Colb M and Parkinson (1985): Unique allelic restriction fragments of the human Ha-ras locus in leucocytes and tumor DNAs of cancer patients. *Nature* 313: 369.
86. Lakhani, S.R. et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. *J Clin Oncol* 20, 2310-8 (2002).

87. Layde PM, Webster LA, Baughman AI et al. (1989): The independent association of parity, age at first full term pregnancy and duration of breastfeeding with the risk of breast cancer. *J Clin Epidemiol* 42:963-73.
88. Leach, M.O. et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). *Lancet* 365, 1769-78 (2005).
89. Lerman C (1994): Psychological issues in genetic testing for breast cancer susceptibility. *Arch. Int. Aged.* 154: 609.
90. Lobaccaro JM, Lumbroso S, Belon S et al. (1993): Androgen receptor gene mutation in male breast cancer. *Hum Mol Genet* 2: 1799.
91. Lynch H and Lynch I (1991): Familial factors and genetic predisposition to cancer: populations' studies. *Cancer Detect Prev* 1: 49.
92. Marra G and Boland CR (1995): Hereditary non-polyposis colorectal cancer: the syndrome, the genes and historical perspectives. *J Natl Cancer Inst* 87: 1114.
93. Longnecker M. (1994): Alcoholic beverage consumption in relation to risk of breast cancer: meta-analysis and review. *Cancer Causes Control* 5:73
94. Longy M and Lacombe D (1996): Cowden disease: report of a family and re-view. *Ann Genet* 39: 35.
95. Lubinski, J. et al. Cancer variation associated with the position of the mutation in the BRCA2 gene. *Fam Cancer* 3, 1-10 (2004).
96. Mann, G.J. et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. *Breast Cancer Res* 8, R12 (2006).
97. Masciari, S. et al. Germline E-cadherin mutations in familial lobular breast cancer. *J Med Genet* 44, 726-31 (2007).
98. McGuire, V. et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. *Am J Epidemiol* 160, 613-8 (2004).
99. McLaughlin, J.R. et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. *Lancet Oncol* 8, 26-34 (2007).
100. Merajver S, Pham T, Caduff, R et al. (1995): Somatic mutations in the BRCA1 gene in sporadic ovarian tumors. *Nature Genet* 9: 43-9.
101. Meyn S (1995): Ataxia-Telangiectasia and cellular responses to DNA damage. *Cancer Res* 55: 5991.

102. Mick R, Begg CB and Amman K (1989): Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapy. *Breast Ca Res Treat* 13: 33.
103. Miki Y, Swensen J, Shattuck-Eidens D et al. (1994): A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 266: 66.
104. Mittendorf R, Longnecker M, Newcomb P et al. (1995): Strenuous physical activity in young adulthood and risk of breast cancer (United States). *Cancer Causes Control* 6: 347.
105. Mokhtar N (1991): *Cancer Pathology Registry 1985-1989*, National Cancer Institute, Cairo University.
106. Muto M, Cramer D, Tangir J et al. (1996): Frequency of the BRCA1 185 de-1AG mutation among Jewish women with ovarian cancer and matched population controls. *Cancer Res.* 56: 1250.
107. Nanda, R. et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. *Jama* 294, 1925-33 (2005).
108. Narod S, Feunteun J and Lynch. H. (1994): Familial breast-ovarian cancer locus on chromosome 17q12-21. *Lancet* 343: 692.
109. Narod S, Ford D, Devilee P et al. (1995): An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. *Am J Hum Genet* 57: 957.
110. Narod S, Ford D, Devilee P et al. (1995): Genetic heterogeneity of breast-ovarian cancer revisited. *Am. J. Hum Genet* 57: 957.
111. Narod S, Lynch H, Conway T et al. (1993): Increasing incidence of breast cancer in family with BRCA1 mutation. *Lancet* 341:1101.
112. NCCN Breast Cancer (1999): Risk-Reduction Guidelines *Oncology* 13:241.
113. Nelen M, Padberg G, Peeters E et al. (1996): Localization of the gene for Cowden disease to 10q22-23, *Nature Genet.* 13: 114.
114. Nelson, H.D., Huffman, L.H., Fu, R. & Harris, E.L. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. *Ann Intern Med* 143, 362-79 (2005). Pal, T. et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. *Cancer* 104, 2807-16 (2005).
115. Newman, B. et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. *Jama* 279, 915-21 (1998).
116. Offit, K. BRCA mutation frequency and penetrance: new data, old debate. *J Natl Cancer Inst* 98, 1675-7 (2006).

117. Offit, K. & Brown, K. Quantitating familial cancer risk: a resource for clinical oncologists. *J Clin Oncol* 12, 1724-36 (1994).
118. O'Regan, R.M. Chemoprevention of breast cancer. *Lancet* 367, 1382-3 (2006).
119. Ottman R, Pike MC, King MC, Henderson BE (1983): Practical guide for estimating risk for familial breast cancer. *Lancet* 2:556-8
120. Parmigiani, G. et al. Validity of models for predicting BRCA1 and BRCA2 mutations. *Ann Intern Med* 147, 441-50 (2007).
121. Petit JY, Le MG and Mouriesse, H. (1993): Breast augmentation and the risk of subsequent breast cancer. *N Engl J Med* 328: 661.
122. Peto, J. et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. *J Natl Cancer Inst* 91, 943-9 (1999).
123. Pierce, L.J. et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. *J Clin Oncol* 24, 2437-43 (2006).
124. Powles T, Eeles R, Ashley S, et al (1998): Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital, tamoxifen randomized chemo-prevention trial. *Lancet* 352:98-101
125. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. *Br J Cancer* 83, 1301-8 (2000).
126. Rahman, N. et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nat Genet* 39, 165-7 (2007).
127. Ratnam, K. & Low, J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. *Clin Cancer Res* 13, 1383-8 (2007)Rebbeck, T.R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. *N Engl J Med* 346, 1616-22 (2002).
128. Rebbeck, T.R. et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol* 22, 1055-62 (2004).
129. Risch, H.A. et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet* 68, 700-10 (2001).
130. Robson, M. & Offit, K. Clinical practice. Management of an inherited predisposition to breast cancer. *N Engl J Med* 357, 154-62 (2007).
131. Robson, M.E. Treatment of hereditary breast cancer. *Semin Oncol* 34, 384-91 (2007).
132. Scheuer, L. et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. *J Clin Oncol* 20, 1260-8 (2002).

133. Schmidt JG (1990): The epidemiology of mass breast cancer screening-plea for a valid measure of benefit. *J Clin Epidemiol* 43: 215.
134. Seal, S. et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. *Nat Genet* 38, 1239-41 (2006).
135. Simar J, Tonin P, Durochet F et al. (1994): Common origins of BRCA1 mutations to Canadian breast and ovarian cancer families. *Nature Genet* 8: 392.
136. Smith S, Easton D, Evans D and Ponder B (1992): Allele losses in the region 17q 12-21 in familial breast and ovarian cancer involve the wild-type chromosome. *Nature Genet* 2: 128.
137. Smith, P. et al. A genome wide linkage search for breast cancer susceptibility genes. *Genes Chromosomes Cancer* 45, 646-55 (2006).
138. Smith, A. et al. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. *J Med Genet* 44, 10-15 (2007).
139. Southey, M.C. et al. BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. *Br J Cancer* 79, 34-9 (1999).
140. Struewing J, Abeliovich D, Perm T et al. (1995): The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent of Ashkenazi Jewish individuals. *Nature Genet* 11: 198.
141. Struewing J, Brody L, Erdos M et al. (1995): Detection of height BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. *Am J Hum Genet* 57: 1.
142. Struewing J, Watson P, Easton D et al. (1995): Primary oophorectomy in inherited breast/ovarian cancer families. *J Nat Cancer Inst Monogr*, n°17: 33.
143. Swift M, Morrel D, Massey R and Chase C (1991): Incidence of cancer in 161 families affected by ataxia-telangiectasia. *N Engl J Med* 325: 1831.
144. Tanako M, Aida H, Ueda H et al (1996): Japanese site specific ovarian cancer families have linkage to chromosome 9q34. *Proc Am Ass Cancer Res* 37: abstract n° 726.
145. Thorlacius S, Olafsdottir G, Tryggvadottir L et al. (1996): A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. *Nature Genet*. 13: 117.
146. Tryggvadottir, L. et al. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. *J Natl Cancer Inst* 98, 116-22 (2006).
147. Turnbull, C. & Rahman, N. Genetic predisposition to breast cancer: past, pre-sent, and future. *Annu Rev Genomics Hum Genet* 9, 321-45 (2008).

148. Turner, N.C. & Reis-Filho, J.S. Basal-like breast cancer and the BRCA1 phenotype. *Oncogene* 25, 5846-53 (2006).
149. Turner, N., Tutt, A. & Ashworth, A. Targeting the DNA repair defect of BRCA tumours. *Curr Opin Pharmacol* 5, 388-93 (2005).
46. Veronesi, U. et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. *J Natl Cancer Inst* 95, 160-5 (2003).
150. Veronesi, A. et al. Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. *BMC Cancer* 5, 70 (2005).
151. Veronesi U, Maisonneuve P, Costa A et al. (1998): Prevention of breast cancer with tamoxifen: preliminary finding from the Italian randomized trial among hysterectomized women. *Lancet* 352:93-97
152. Vogel, V.G. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *Jama* 295, 2727-41 (2006). Wooster, R. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. *Science* 265, 2088-90 (1994).
153. Wanebo H, Senofsky G, Fechner R et al. (1985): Bilateral breast cancer. Risk reduction by contralateral biopsy. *Ann. Surg.* 201: 667.
154. Watson P and Lynch H (1993): Extracolonic cancer in hereditary non-polyposis colorectal cancer. *Cancer* 71: 677.
155. Wooster R, Bignell G, Lancaster J et al. (1995): Identification of the breast cancer susceptibility gene BRCA2. *Nature* 378: 789.
156. Wooster R, Mangion J, Eeles R et al. (1992): A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenshtein syndrome. *Nature Genet* 2: 132.
157. Wooster R, Neuhausen SL, Mangion J et al. (1994): Localization of a breast cancer susceptibility gene (BRCA2) to chromosome 13q12-13q13. *Science* 265: 2088.
158. Yarden, R.I. et al. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. *Breast Cancer Res Treat* (2007).
159. Ziegler L and Kroll S (1991): Primary breast cancer after prophylactic mastectomy. *Am J Clin Oncol* 14:451.
- a. Screening Diagnosis Imaging Staging, Pathology Prognostic

160. Albain K, Barlow W, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100) (abstract 10). Program and abstracts of the 30th Annual San Antonio Breast Cancer Symposium, Dec 13-16, 2007.
161. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L and McGuire WL (1992): Her2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. *J Clin Oncol* 10: 599.
162. American Joint Committee on Cancer (1992): Manual for staging of cancer. Philadelphia: J. B. Lippincott Company, 4th ed. p 149.
163. Andersson I, Aspegren K and Janzon L et al. (1988): Mammographic screening and mortality from breast cancer: the Malm mammographic screening trial. *Br Med J* 297: 943.
164. Association of Directors of Anatomic and Surgical Pathology (1993): Immediate management of mammographically detected breast lesions. *Am J Surg Pathol* 17 (8): 850.
165. Ashikari R, Huvos AG and Snyder RE (1977): Prospective study of non infiltrating carcinoma of the breast. *Cancer* 39: 435.
166. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. *J Clin Oncol* 2000, 18 : 3495-3502
167. Azzopardi JG, Chpik OF, Hartmann WH et al. (1986): Histologic typing of breast tumors. *Am J Clin Pathol* 78: 806.
168. Baker LH (1982): Breast cancer detection demonstration project: five years Summary report. *CA* 32: 194.
169. Balleyguier C, Ayadi S, Van Nguyen K, Vanel D, Dromain C, Sigal R. BIRADS classification in mammography. *Eur J Radiol* 2007, 61 : 192-194
170. Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. *Breast Cancer Res Treat* 2002, 72 : 145-152
171. Bartella L, Morris EA. Advances in breast imaging: magnetic resonance imaging. *Curr Oncol Rep* 2006, 8 : 7-13
172. Bartella L, Smith CS, Dershaw DD, Liberman L. Imaging breast cancer. *Radiol Clin North Am* 2007, 45 : 45-67
173. Bassett LW, Kim CH. Breast imaging: mammography and ultrasonography. *Magn Reson Imaging Clin N Am* 2001, 9 : 251-71, v

174. Bassett LW, Mahoney MC, Apple SK. Interventional breast imaging: current procedures and assessing for concordance with pathology. *Radiol Clin North Am* 2007, 45 : 881-94, vii
175. Bazzocchi M, Zuiani C, Panizza P, Del Frate C, Soldano F, Isola M, Sardanelli F, Giuseppetti GM, Simonetti G, Lattanzio V, Del Maschio A. Contrast-enhanced breast MRI in patients with suspicious microcalcifications on mammography: results of a multicenter trial. *AJR Am J Roentgenol* 2006, 186 : 1723-1732
176. Beahrs OH, Shapiro S and Smart C et al. (1979): Summary report to the working group to review the National Cancer institute-American Cancer So-ciety Breast Cancer Detection Demonstration Projects. *J Nat Cancer Inst* 62: 641.
177. Bedwinek JM, Lee J, Fineberg B and Ocwieza M (1981): Prognostic indicators in patients with isolated local regional recurrence of breast cancer. *Cancer* 47: 2232.
178. Belli P, Costantini M, Romani M, Marano P, Pastore G. Magnetic resonance imaging in breast cancer recurrence. *Breast Cancer Res Treat* 2002, 73 : 223-235
179. Berg JW (1985): The significance of axillary node levels in the study of breast cancer. *Cancer* 8: 776.
180. Berg WA. Overview of breast imaging. *Semin Roentgenol* 2001, 36 : 180-186
181. Berg WA. Rationale for a trial of screening breast ultrasound: American Col-lege of Radiology Imaging Network (ACRIN) 6666. *AJR Am J Roentgenol* 2003, 180 : 1225-1228
182. Berg WA, Gutierrez L, NessAiver MS, Carter WB, Bhargavan M, Lewis RS, Ioffe OB. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. *Radiology* 2004, 233 : 830-849
183. Berg WA. Beyond standard mammographic screening: mammography at age extremes, ultrasound, and MR imaging. *Radiol Clin North Am* 2007, 45 : 895-906, vii
184. Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Bohm-Velez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. *JAMA* 2008, 299 : 2151-2163
185. Berman CG. Recent advances in breast-specific imaging. *Cancer Control* 2007, 14 : 338-349
186. Berrino F, Bouchardy C and Sasco A (1995): Screening for breast cancer in premenopausal women. Who should decide? *Int J Cancer* 60:153.
187. Berry D.A., Cronin K.A., Plevritis S.K. et al. Effect of Screening and Adjuvant Therapy Mortality from Breasts Cancer. *N. Engl. J. Med.* 2005, 353 : 1784-92

188. Betsill WL Jr, Rosen PP, Lieberman PH and Robbins GF (1975): Intraductal carcinoma of the breast. A comparative study. *Am J Surg* 130: 667.
189. Bigenwald RZ, Warner E, Gunasekara A, Hill KA, Causer PA, Messner SJ, Eisen A, Plewes DB, Narod SA, Zhang L, Yaffe MJ. Is mammography adequate for screening women with inherited BRCA mutations and low breast density? *Cancer Epidemiol Biomarkers Prev* 2008, 17 : 706-711
190. Bleicher RJ, Morrow M. MRI and breast cancer: role in detection, diagnosis, and staging. *Oncology (Williston Park)* 2007, 21 : 1521-8, 1530
191. Bloodgood TC (1908): The clinical and pathological differential diagnosis of diseases of the female breast. *Am J Med Sci* 135: 157.
192. Bloom H JG and Richardson WW (1957): Histological grading and prognosis in breast cancer *Br J Cancer* 11: 359.
193. Bosari S, Lee AKC, Tahan SR, Figoni MAT, Wiley BD, Heatley GJ and Silverman ML (1992): DNA flow cytometric analysis and prognosis of axillary lymph node-negative breast carcinoma. *Cancer* 70: 1943.
194. Boyages J, Recht A, Connolly JL, Schnitt SI, Gelman R, Kooy H, Love S, Os-teen RT, Cady B, Silver B and Harris JR (1990): Early breast cancer: predictors of breast recurrence for patients treated with conservative surgery and radiation therapy. *Radiother Oncol* 19: 29.
195. Boyer B, Lévy L, Piguet JC, Balleyguier C: Systèmes CAD en mammographie : performances et place dans les campagnes de dépistage- Revue de la littérature. In : Isnard A, Travade A (eds): *Innovations technologiques et bonnes pratiques en sénologie*. Ed Fusium, 2006, pp 82-90
196. Brettes JP. [Presentation of the French translation of the Breast Imaging Reporting System and Data System (BI-RADS)]. *Gynecol Obstet Fertil* 2005, 33 : 839-841
197. Breast. In: American Joint Committee on Cancer.: *AJCC Cancer Staging Manual*. 6th ed. New York, NY: Springer, 2002, pp 171-180.
197. Brekelmans CTM, Seynaeve C, Bartels CCM et al. (2001): Effectiveness of breast cancer surveillance in BRCA1 / 2 genes and women with high familial risk. *J Clin Oncol* 19: 924-930.
198. Bruce J, Carter DC and Fraser J (1970): Patterns of recurrent disease in breast cancer. *Lancet* 1: 433.
199. Bull AR and Campbell MJ (1991): Assessment of the psychological impact of a breast screening programme. *Br J Radiol* 64:510.
200. Bunting JS, Hemsted EH and Kremer JK (1976): The pattern of spread and survival in 596 cases of breast cancer related to clinical staging and histological grade. *Clin Radiol* 27: 9.

201. Cammoun H, Contesso G. and Rouëssé J (1972): Les adénocarci-nomes cylindromateux du sein. *Ann Pathol* 17:143.
202. Camplejohn RS, Ash CM, Gillett CE, Raikundalia B, Barnes DM, Gregory WM, Richards MA, and Millis RR (1995): The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single center. *Br J Cancer* 71: 140.
203. Carstens PHB (1978): Tubular carcinoma of the breast. A study of frequency. *Am J Clin Pathol* 10: 204.
204. Carter D and Smith RL (1977): Carcinoma in situ of the breast. *Cancer* 40: 1189.
205. Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE. The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. *Breast Cancer Res Treat* 2001, 68 : 45-54
206. Chen JH, Mehta RS, Carpenter PM, Nalcioglu O, Su MY. Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy. *J Clin Oncol* 2007, 25 : 5667-5669
207. Chevallier B, Asselain B, Kunlin A, Veyret C and Bastit P (1986): Rapidly Growing Breast Cancer: Results of a Retrospective Analysis with a study of Prognostic Factors. *Bull-Cancer (Paris)* 73(2): 139.
208. Chereil P, Hagay C, Benaim B, De Maulmont C, Engerand S, Langer A, Talma V. [Mammographic evaluation of dense breasts: techniques and limits.]. *J Radiol* 2008, 89 : 1156-1168
209. Ciatto S, Houssami N, Apruzzese A, Bassetti E, Brancato B, Carozzi F, Catarzi S, Lamberini MP, Marcelli G, Pellizzoni R, Pesce B, Risso G, Russo F, Scorsolini A. Reader variability in reporting breast imaging according to BI-RADS assessment categories (the Florence experience). *Breast* 2006, 15 : 44-51
210. Clark GM (1992): Integrating prognostic factors. *Br Cancer Res Treat* 22: 187.
211. Clark GM and McGuire WL (1988): Steroid receptors and other prognostic factors in primary breast cancer. *Semin Oncol* 15: 20.
212. Clayton F (1991): Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. *Cancer* 68: 1309.
213. Cockburn J, Staples M, Hurley S and Deluyse T (1994): Psychological consequences of screening mammography. *Journal of Medical Screening* 1:7.
214. Contesso G. (1980): Définition et devenir des lésions frontières du sein, hyperplasies atypiques et carcinomes in situ. *J Gyneco Obstet Biol Re-prod* 9: 101.
215. Contesso G and Petit JY (1979): Les adénocarcinomes intra-canalaires non infiltrants du sein. *Bull. Cancer (Paris)* 66: 81.

- 216 Contesso G, Fontaine F and Petit JY (1977): Les Disséminations In-tramammaires des Carcinoma du sein. Bull Cancer 64: 5. Quoted in Contesso et al. (1984).
- 217 Contesso G, Mouriesse H, Friedman S Genin J, Sarrazin D and Rouëssé J (1987): The importance of histologic grade in long term prognosis of breast cancer: a study of 1010 patients uniformly treated at the Institut Gustave-Roussy J Clin Oncol 5: 1378.
- 218 Contesso G, Mouriesse, H. and Petit JY (1990): Non palpable breast cancer: the point of view of the pathologist. J B R - B T R. 73: 329.
- 219 Contesso G, Omar Sh, Ibrahim AS, Mouriesse H, Tawfik H and Ga-reer WY (1982): Prospective Inter-comparative study of Breast Cancer between Egypt and France. Egypt J Oncol 2:55.
- 220 Contesso G, Rouëssé J and Mouriesse H. (1984): Prognostic Factors of Breast Cancer. In: Contesso G and Omar Sh (ed). Breast Cancer - A Com-prehensive Approach. Year Book of Clinical Medicine. Published by The Cairo Medical Syndicate. P. 189.
- 221 Coombs NJ, Boyages J. Multifocal and multicentric breast cancer: does each focus matter? J Clin Oncol 2005, 23 : 7497-7502
- 222 Cosgrove DO, Kedar RP and Bamber JC et al (1993): Breast diseases: color Doppler US in differential diagnosis. Radiology 189: 99.
223. Costa J, Weber BL, Levine PH et al. (1982): Histopathological features of rapidly progressing breast carcinoma in Tunisia: A study of 94 cases. Int J Cancer 30: 35.
224. Costantini M, Belli P, Lombardi R, Franceschini G, Mule A, Bonomo L. Characterization of solid breast masses: use of the sonographic breast imaging reporting and data system lexicon. J Ultrasound Med 2006, 25 : 649-659
225. Davis BOW, Gelber RD, Goldhirsch A, Hartmann H, Locher GW and Reed R (1986): Prognostic Significance of Tumor Grade in Clinical Trials of Adjuvant Therapy for Breast Cancer with Axillary Lymph Node Metastasis. Cancer 58(12): 2662.
226. de Gery S, Perret F, Espie M, Frijia J. [Breast imaging and biopsy procedures in the diagnosis of breast cancer]. Presse Med 2003, 32 : 125-133
227. De Koning H, Boer R and Warmerdam P (1995): Quantitative Interpretation of age specific mortality reduction from the Swedish breast cancer screening trials. JAMA 274:1
228. De La fontan B, Daures JP and Salicru B et al. (1994): Isolated clustered microcalcifications: diagnostic value of mammography-series of 400 cases with surgical verification. Radiology 190: 419.
229. Dershaw DD. Breast imaging and the conservative treatment of breast cancer. Radiol Clin North Am 2002, 40 : 501-516

230. Dilhuidy MH, Le Treut A and Guibert JL (1991): Mammography and indications for excisional therapy. In: Le Treut A, Dilhuidy MH. Eds. Mam-mography: a guide to interpretation. Mosby Yearbook: St Louis 182.
231. Dilhuydy MH, Le Treut A, Dilhuydy JM and Kind M (1993): The Breast in Imaging strategies in oncology by Vanel D and Stark D Ed. London, Martin Dunitz.
232. Dixon JM, Anderson TJ, Page DL et al. (1982): Infiltrating lobular carcinoma of the breast. *Histopathology* 6: 149.
233. Dilhuydy MH. Breast imaging reporting and data system (BI-RADS) or French "classification ACR" What tool for what use? A point of view. *Eur J Radiol* 2007, 61 : 187-191
234. Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, Myles JP, Warwick J. Overdiagnosis and overtreatment of breast cancer: es-timates of overdiagnosis from two trials of mammographic screening for breast cancer. *Breast Cancer Res* 2005, 7 : 258-265
235. Easson EC (1968): In *Prognostic Factors in Breast Cancer*. E & S. Livingston Ltd., Edinburgh, p. 118.
236. El Khouli RH, Jacobs MA, Bluemke DA. Magnetic resonance imag-ing of the breast. *Semin Roentgenol* 2008, 43 : 265-281
237. De Angelis LM and Payne R (1987): Lymphomatous meningitis pre-senting as atypical cluster headache. *Pain* 30: 211.
238. Elledge R, Fuqua SAW, Clark GM, Pujol P, and Allred DC (1993): The role and prognostic significance of p53 alterations in breast cancer *Breast. Cancer Res Treat* 27: 95.
239. Elston CW, and Ellis IO (1991): Pathological prognostic factors in breast cancer 1. The value of histological grade in breast cancer Experience from a large study with long-term follow-up. *Histopathology* 19: 403.
240. Elwood JM, Cox R, and Richardson AK (1995): The effectiveness of breast cancer screening by mammography in younger women. *Online J Cur Clin Trials Doc* NR 32.
241. Ekblom P, Miettinen M, Forsman L, et al. (1984): Basement mem-brane and apocrine epithelial antigens in differential diagnosis between tubu-lar carcinoma and sclerosing adenosus of the breast *J. Clin Pathol* 37: 357.
242. El-Bolkainy MN, Mansour MA and Soliman OA (1972): The axillary lymph nodes in breast cancer. *Med J Cairo University* 40:27.
243. Farrow JH (1970): Current concepts in the detection and treatment of the earliest of the early breast cancers. *Cancer* 25: 468.

244. Fechner RE (1975): Histologic variants of infiltrating lobular carcinoma of the breast. *Hum Pathol* 6: 373.
245. Fentimar IS and Gregory WM (1994): Peri-operative hormones and prognosis in breast cancer. *Eur J Cancer* 30 A (12): 1392.
246. Fenton JJ, Taplin SH, Carney PA, Abraham L, Sickles EA, D'Orsi C, Berns EA, Cutter G, Hendrick RE, Barlow WE, Elmore JG. Influence of computer-aided detection on performance of screening mammography. *N Engl J Med* 2007, 356 : 1399-1409
247. Flechter SW, Black W, Harris R et al. (1993): Report of the international workshop on screening breast cancer. *Nat Cancer Inst* 85(20): 1644.
248. Fischer U (2001): "Inpatient comparison of microcalcifications: Full-field digital mammography vs. screen film mammography". Abstract # B-0408 presented at ERC 2001.
249. Fisher B and Slack N (1970): Number of Lymph Nodes examined and the Prognosis of Breast Carcinoma, *Surg Gyn Obst* 131:79.
250. Fielding LP and Henson DE (1993): Multiple prognostic factors and outcome analysis in patients with cancer Communication from the American Joint Committee of Cancer. *Cancer* 71: 2426.
251. Fisher B, Gunduz N, Costantino J, Fisher ER, Redmond C, Mamounas EP and Siderits R (1991): DNA flow cytometric analysis of primary operable breast cancer Relationship of ploidy and S-phase fraction to outcome of patients in NSABP B-04. *Cancer* 68: 1465
252. Fisher B, Redond C and Brown A (1986): Tumor Nuclear Grade, Estrogen Receptor: Their value alone or in combination as indicators of outcome following Adjuvant Therapy for Breast Cancer. *Breast Cancer Res Treat* 7(3): 147.
253. Fisher ER, Gregorio RM, Fisher B, et al. (1975): The pathology of breast cancer. A syllabus derived from findings of the National Surgical Adjuvant breast project (Protocol No 4) *Cancer* 36: 1
254. Fisher ER, Gregorio RM, Remond E, et al. (1977): Tubulo-lobular invasive breast cancer. A variant of lobular invasive cancer. *Hum Pathol* 8: 679.
255. Fisher ER, Redmond C, Fisher B, and Bass G (1990): Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP). *Cancer* 65: 2121.
256. Fisher ER, Sass R, Fisher B, et al. (1986): Pathologic findings from National Surgical adjuvant breast project (Protocol 6). Relation of multicentricity to local breast recurrence. *Cancer* 57: 1717.
257. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF. Recommendations on the use of 18F-FDG PET in oncology. *J Nucl Med* 2008, 49 : 480-508

258. Foote FN and Stewart FN (1941): Lobular carcinoma in situ: a rare form of mammary cancer. *Am J Pathol* 17: 491.
259. Fornage BD, Coan JD, David CL. Ultrasound-guided needle biopsy of the breast and other interventional procedures. *Radiol Clin North Am* 1992, 30 : 167-185
260. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D and Harris AL (1994): The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. *Breast Cancer Res Treat* 29:41.
261. Frierson BF (1991): Ploidy analysis and S-phase fraction determination by flow cytometry of invasive adenocarcinomas of the breast. *Am Surg Pathol* 15: 358.
262. Frouge C, Guinebretiere JM, Leguen O, Antoun H, Contesso G and Blery M (1995): Repérage avec matériel non ionisant : Limite de sémiologie de la prise de contrastes en IRM du sein. *J Le sein* 5 No. 2: 124.
263. Frouge C, Tristant H, Guinebretiere JM et al. (1995): Mammographic lesions suggestive of radial scars: microscopic findings in 40 cases. *Radiology* 195: 623.
264. Gallager HS and Martin JE (1971): An orientation to the concept. of minimal breast cancer. *Cancer* 28:1505.
265. Gardin G, Alama A, Rosso R, Campora E, Repetto L, Pronzato P, Merlini L, Naso C, Camoriano A, Meazza R, Barbieri F, Baldini E, Giannessi PG, and Conte PF (1994): Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. *Breast Cancer Res Treat* 32: 311.
266. Gasparini G and Harris AL (1995): Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. *J Clin Oncol* 13: 765.
267. Gasparini G, Gullick WJ, Maluta S, et al; (1994): c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma - a non seeable immunocytochemical study. *Eur J Cancer* 30: 16.
268. Gasparini G, Pazza F, Bevilacqua E, and Sainsburm JRC (1992): Growth fraction (Ki-67 antibody determination in early stage breast carcinoma: histologic clinical and prognostic correlations. *The Breast* 1: 92.
269. Genin J, Contesso G and Petit JY (1978): Les écoulements sanglants du mamelon. *Rev. Prat, (Paris)* 8 (13) : 1023.
270. Gilles R, Zafrani B, Guinebretiere JM et al (1995): Ductal carcinoma in situ: MR imaging-histopathologic correlation. *Radiology* 196: 415.

271. Gilles R, Guinebretiere JM, Lucidarme O et al. (1994): Non palpable breast tumors: diagnosis by dynamic contrast-enhanced subtraction. *MRI Ra-diology* 191: 625
272. Gilles R; Mesurolles B, Lesnik A, Rigaud C, Guinebretiere JM, Mas-selot JM, Contesso G and Vanel D (1995): Repérage préopératoire des lésions mammaires non palpables: technique du compresseur fenêtre. *J Le sein* 5 nos. 1: 18.
273. Gnant MFX, Blijham G, Reiner A, Reiner G, Reynders M, Shutte B, van Asche C, Steger G, and Jakesz R (1992): DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10 year results of a randomized study. *Eur J Cancer* 28: 711.
274. Good WF, Abrams GS, Catullo VJ, Chough DM, Ganott MA, Hakim CM, Gur D. Digital breast tomosynthesis: a pilot observer study. *AJR Am J Roentgenol* 2008, 190 : 865-869
275. Gohagan JK, Darby WP and Spitznageel EL et al. (1986): Radiogenic breast cancer effects of mammographic screening, *J Nat Cancer Inst* 77: 71.
276. Going JJ, Anderson TJ, Crocker PR and Levison DA (1990): Wed-dellite calcification in the breast: eighteen cases with implications for breast cancer screening. *Histopathology* 16: 119.
277. Gordts SL, Neven P, Van Hooff I et al (2000): the immunocytochemical versus cytosol measurement of the estrogen receptor in invasive breast cancer tissue. *Eur J Cancer* 36 (suppl 4): S20-S21.
278. Gouldnig H, Pnider S, Cannon P, Pearson D, Nicholson R, Snead D, Bell J, Elston WE, Robertson JF, Blarney RW and Ellis IO (1995): A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. *Hum Pathol* 26: 291.
279. Greenberg HS, Deck MDF, Vikram B et al. (1981): Metastasis to the base of the skull: clinical findings in 43 patients. *Neurology* 31: 530.
280. Greene GL, Sobel NB and King WJ et al. (1984): Immunochemical studies of estrogen receptors. *J Steroid Biochen.* 20: 51.
2281. Greenstein Orel S, Schnall MD, Newman RW, Powell CM, Torosian MH and Rosato EF (1994): MR imaging-guided localization and biopsy of breast lesions: initial experience. *Radiology* 193: 97.
282. Guller U, Nitzsche EU, Schirp U, Viehl CT, Torhorst J, Moch H, Langer I, Marti WR, Oertli D, Harder F, Zuber M. Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet! *Breast Cancer Res Treat* 2002, 71 : 171-173
283. Gulsun M, Demirkazik FB, Ariyurek M. Evaluation of breast micro-calcifications according to Breast Imaging Reporting and Data System criteria and Le Gal's classification. *Eur J Radiol* 2003, 47 : 227-231

284. Guo Y, Cai YQ, Cai ZL, Gao YG, An NY, Ma L, Mahankali S, Gao JH. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. *J Magn Reson Imaging* 2002, 16 : 172-178
285. Gur D. Tomosynthesis: potential clinical role in breast imaging. *AJR Am J Roentgenol* 2007, 189 : 614-615
286. Gusterson BA, Gelber RD, Goldhirsch A et al (1992): Prognostic importance of c-erbB-2 expression in breast cancer. *Clin Oncol* 10: 1049.
287. Haagensen CD, Lattes R and Bodian C (1978): Lobular neoplasia (so called lobular carcinoma in situ) of the breast. *Cancer* 42: 737.
288. Hagay C, Cherel P, de Maulmont C et al. (1993): Contrast-enhanced CT mammography: evaluation in local breast cancer recurrence. *Radiology* 189: 406.
289. Hall J, Lee M, Newman B (1990): Linkage of early-onset familial breast cancer to chromosome 17q21. *Science* 250: 1684.
290. Harms SE, Flaming DP, Evans WP, Harries S A and Bown S (1994): MR imaging of the breast: Current status and future potential. *A J R* 163: 1039.
291. Harper AP, Kelly Fry E, Noe J et al. (1983): Ultrasound in the evaluation of solid breast masses. *Radiology* 146: 731.
292. Harris M, Wells S and Vasudev KS (1978): Primary signet ring cell carcinoma of the breast. *Histopathology* 2: 171.
293. Harris R and Leininger L (1995): Clinical strategies for breast cancer screening: weighing and using the evidence. *Annals of Internal Medicine* 122: 539.
294. Harvey JM, Calrk GM, Osborne CK, Allred DC (1999): Estrogen receptor status by immunohistochemistry is superior to ligand-binding assay for predicting response to adjuvant therapy in breast cancer *J Clin Oncol* 17: 1474-1485
295. Haves DF, Bast RC, Desch CE et al. (1996): Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. *J Natl Cancer Inst* 88:1456
296. Hawkins RA (2000) How best to express estrogen receptor activity. *Eur J Cancer* 36 (Suppl 4) S21-S23.
2297. Hayward J (1981): The surgeon's role in primary breast cancer. *Breast Cancer Research and Treatment* 1:27.
298. Helin H, Helle M, Kalthomieni O et al. (1989): Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma, *Cancer* 63: 1761.

299. Hellerhoff K, Schlossbauer T, Herzog P, Reiser M. [Interventional MRI of the breast. Indications, technique, results and perspectives]. *Radiologe* 2008, 48 : 367-374
300. Hendrick RE, Cole EB, Pisano ED, Acharyya S, Marques H, Cohen MA, Jong RA, Mawdsley GE, Kanal KM, D'Orsi CJ, Rebner M, Gatsonis C. Accuracy of soft-copy digital mammography versus that of screen-film mammography according to digital manufacturer: ACRIN DMIST retrospective multireader study. *Radiology* 2008, 247 : 38-48
301. Henrot P: Techniques d'imagerie du futur. SOFMIS Nancy, 2008 :49-58
302. Heywang-Koebrunner S (1994): Contrast-enhanced magnetic resonance imaging of the breast. *Invest Radiol* 29: 94.
303. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? *J Clin Oncol* 2008, 26 : 712-720
304. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van den Vijver MJ and Zafrani B (1994): EUSOMA. Ductal carcinoma in Situ: a proposal for a new classification. *Seminars in Diagnostic Pathology* 11: 167.
305. Holland R, Velling SH, Mravunach M and Hendriks JR (1985): Histologic multifocality of Tis and T1-2 breast carcinomas. Implications for clinical trials of breast conservative surgery. *Cancer* 56: 979.
306. Homer MJ. Breast imaging, standard of care, and the expert. *Radiol Clin North Am* 2004, 42 : 963-74, viii
307. Huber S, Delorme S, Knopp MV et al. (1994): Breast tumors: computer-assisted quantitative assessments with color Doppler US. *Radiology* 192: 797.
308. Hurley S and Kaldor J (1992): The benefits and risks of mammographic screening for breast cancer. *Epidemiologic Reviews*. The Johns Hopkins University School of Hygiene and Public Health 14: 101.
309. Israel HJ (1976): Cancer in the Cold Breast Thermogram. *Am J Roentgenol* 127: 793.
310. Issacs JT (1986): Clonally Heterogeneity and its implications In: Stoll BA (ed). *Breast Cancer Treatment and Prognosis*- Blackwell Scientific Publications, Oxford, London, Edinburgh, p. 45.
311. Itoh A, Ueno E, Tohno E, Kamma H, Takahashi H, Shiina T, Yama-kawa M, Matsumura T. Breast disease: clinical application of US elastography for diagnosis. *Radiology* 2006, 239 : 341-350
312. Jackman RJ, Birdwell RL, Ikeda DM. Atypical ductal hyperplasia: can some lesions be defined as probably benign after stereotactic 11-gauge vacuum-assisted biopsy, eliminating the recommendation for surgical excision? *Radiology* 2002, 224 : 548-554

313. Johson H., Johansson R., Lenner P. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. *Int J cancer* 2005, 117: 842-7.
314. Jotli GS, Petit JY and Contesso G (1986): Minimal breast cancer: a clinically meaningful term? *Sem Oncol* 13: 384.
315. Kaiser WA, Pfeleiderer SO, Baltzer PA. MRI-guided interventions of the breast. *J Magn Reson Imaging* 2008, 27 : 347-355
316. Kaplan EI and Meier P (1938): Non parametric estimation from in-complete observations. *J Am Stat Assoc* 53: 457.
317. Kaplan JG, DeSouza TG and Farkash A et al. (1990): Leptomeningeal metastases: comparison of clinical features and laboratory of solid tumors, lymphomas and leukemias. *Journal of Neurology* 9: 225.
318. Kerlikowske K, Grady D, Rubin S, et al. (1995): Efficacy of screening mammography, a meta-analysis. *JAMA* 273-2:149.
319. Khalkhali I, Vargas HI. The role of nuclear medicine in breast cancer detection: functional breast imaging. *Radiol Clin North Am* 2001, 39 : 1053-1068
320. Kieback D, Tong X, Konig R et al. (1996): A complex of mutations in the human progesterone receptor gene is associated with increased risk of non-familial breast and ovarian cancer but not of uterine cancer. *Proc. Am. Ass. Cancer Res.* 37: abstract n° 1704.
321. Kinne WK, Dershaw DD and Rosen PP (1991): Needle localization. In Harris JR ed. *Breast diseases*. Philadelphia: J. B. Lippincott Company.
322. Koelliker SL, Chung MA, Mainiero MB, Steinhoff MM, Cady B. Axillary lymph nodes: US-guided fine-needle aspiration for initial staging of breast cancer--correlation with primary tumor size. *Radiology* 2008, 246 : 81-89
323. Kopans DB. Breast imaging and the symptomatic patient: enough with the "diagnostic" mammography. *AJR Am J Roentgenol* 2003, 181 : 1423-1424
324. Kopans DB, Swann CA, White G et al. (1959): Asymmetric breast tissue. *Radiology* 171: 639.
325. Kuiper GGJM, Enmark E, Peltö-Huikko M, Nilsson S, Gustafsson JA (1996): Cloning of a novel estrogen receptor expressed in rat prostate and ovary. *Proc Natl Acad Sci* 93:5925-5930
326. Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, Hans D, Bressac C, Roth J and Spitalier JM (1990): Risk factors of breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapy *Cancer* 65: 1867.
327. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. *N Engl J Med* 2004, 351 : 427-437

328. Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, Kuhn W, Schild HH. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.
329. Kwak JY, Kim EK, Park HL, et al. Application of the breast imaging reporting and data system final assessment system in sonography of palpable breast lesions and reconsideration of the modified triple test. *J Ultrasound Med* 2006, 25 : 1255-1261
330. Lagios MD, Westdahl PR and Margolin FR (1982): Duct carcinoma in situ. *Cancer* 50:1309.
331. Langer A: Contribution de la mammographie et de l'échographie au bilan d'extension locale des cancers du sein. In : Grumbach Y (ed): *La Prise en charge des cancers du sein : l'implication du radiologue*. SOFMIS, Nancy, Palais des congrès, 22-24 mai. Nancy, Bialec, 2008, pp 23-27
332. Langston A, Malone K, Thompson B et al. (1996): BRCA1 mutations in a population-based sample of young women with breast cancer. *New Eng J Med* 33, 4: 137.
333. Lattes SR (1980): Lobular neoplasia (lobular carcinoma in situ) of the breast. A histological entity of controversial clinical significance. *Path Res Pract* 166: 415.
334. LaTrenta LR, Menell JH, Morris EA, Abramson AF, Dershaw DD, Liberman L. Breast lesions detected with MR imaging: utility and histopathologic importance of identification with US. *Radiology* 2003, 227 : 856-861
335. Lazarus E, Mainiero MB, Schepps B, Koelliker SL, Livingston LS. BI-RADS lexicon for US and mammography: interobserver variability and positive predictive value. *Radiology* (2006), 239 : 385-391
336. Le Doussal V, Tubiana-Hulin M, Friedman S, et al. (1989): Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR) An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. *Cancer* 64: 1914.
337. Le Gal M, Chavanne G and Pellier D: Diagnostic value of clustered microcalcifications discovered by mammography (a propose of 277 cases with histological verification and without a palpable breast tumors. *Bull Cancer (Paris)* (1981)71: 51.
338. Leach MO, Boggis CR, Dixon et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). *Lancet* 2005, 365 : 1769-1778
339. Leake R Detection of the estrogen receptors (ER): immunohistochemical versus cytosol measurements. *Eur J Cancer* 2000 36 (Suppl 4), S 18-S 19.
340. Leconte I, Fella L. [US and dense breasts: Where do we stand?]. *J Radiol* 2008, 89 : 1169-1179
341. Lee BJ and Tannenbaum NE: Inflammatory carcinoma of the Breast. *Surg Gyn Ob* 192439: 580.

342. Lee HJ, Kim EK, Kim MJ, Youk JH, Lee JY, Kang DR, Oh KK. Ob-server variability of Breast Imaging Reporting and Data System (BI-RADS) for breast ultrasound. *Eur J Radiol* 2008, 65 : 293-298
343. Lee SG, Orel SG, Woo IJ, et al. MR imaging screening of the contra-lateral breast in patients with newly diagnosed breast cancer: preliminary re-sults. *Radiology* 2003, 226 : 773-778
344. Lehman CD, Deperi ER, Peacock S, et al. : J. Clinical experience with MRI-guided vacuum-assisted breast biopsy. *AJR Am J Roentgenol* 2005, 184 : 1782-1787
345. Lehman CD, Blume JD, Thickman D, et al. Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Con-sortium (IBMC) trial. *J Surg Oncol* 2005, 92 : 9-15
346. Lehman CD, Gatsonis C, Kuhl CK, et al.. MRI evaluation of the con-tralateral breast in women with recently diagnosed breast cancer. *N Engl J Med* 2007, 356 : 1295-1303
347. Leung JW. New modalities in breast imaging: digital mammography, positron emission tomography, and sestamibi scintimammography. *Radiol Clin North Am* 2002, 40 : 467-482
348. Liberman L, Holland AE, Marjan D, et al. : Underestimation of atyp-ical ductal hyperplasia at MRI-guided 9-gauge vacuum-assisted breast biopsy. *AJR Am J Roentgenol* 2007, 188 : 684-690
349. Liberman L, Menell JH. Breast imaging reporting and data system (BI-RADS). *Radiol Clin North Am* 2002, 40 : 409-30, v
350. Liberman L, Morris EA, Dershaw DD, et al. MR imaging of the ipsi-lateral breast in women with percutaneously proven breast cancer. *AJR Am J Roentgenol* 2003, 180 : 901-910
351. Liberman L, Morris EA, Kim CM, et al.. MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. *AJR Am J Roentgenol* 2003, 180 : 333-341
352. Liberman L, Sama MP. Cost-effectiveness of stereotactic 11-gauge directional vacuum-assisted breast biopsy. *AJR Am J Roentgenol* 2000, 175 : 53-58
353. Lidereau R, Mathieu-Mahul D, Theillet C et al. Presence of an allelic EcoRI restriction fragment of the c-mos locus in leucocytes and tumor cell DNAs of breast cancer patients. *Proc Natl Acad Sci USA* 1995: 82: 7068.
354. Linell F, Ljungbergerrg O and Andersson E Breast carcinoma: as-pects of early stages, progression and related problems. *Acta Pathologica et Microbiologica Scandinavica*. Section A: 1980: Suppl 272.
355. Lipponen P, Ji H, Aaltomaa S, et al p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. *Int Can-cer* 1993: 55: 51

356. Mameri CS, Kemp C, Goldman SM, et al. Impact of breast MRI on surgical treatment, axillary approach, and systemic therapy for breast cancer. *Breast J* 2008, 14 : 236-244
357. Mann RM, Kuhl CK, Kinkel K, et al. MRI: guidelines from the European Society of Breast Imaging. *Eur Radiol* 2008, 18 : 1307-1318
358. Mansour EG, Ravdin PM and Dressler L: Prognostic factors in early breast carcinoma. *Cancer* 1994 74: 3 81.
359. Mellink WA, Holland R, Hendriks JH, et al. The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer. *Cancer* 1991, 67 : 1844-1848
360. Mesurolle B, Bining HJ, El Khoury et al. Contribution of tissue harmonic imaging and frequency compound imaging in interventional breast sonography. *J Ultrasound Med* 2006, 25 : 845-855
361. Miller DG (1976): *The Early Diagnosis of Cancer*. 3rd Ed. Vol. II, Sydney Co.
362. Moon WK, Im JG, Noh DY, Han MC. Nonpalpable breast lesions: evaluation with power Doppler US and a microbubble contrast agent-initial experience. *Radiology* 2000, 217 : 240-246
363. Morris EA, Liberman L, Ballon DJ, et al.. MRI of occult breast carcinoma in a high-risk population. *AJR Am J Roentgenol* 2003, 181 : 619-626
364. Mouriquand J (1993): *Diagnosis of non palpable breast lesions. Ultrasound-guided fine-needle aspiration*. Basel, Switzerland.
365. Murray CJL, Lopez AD (1997): Mortality by cause for eight regions of the world: Global Burden of Disease Study. *Lancet* 349:1269-76.
366. Muscolino G, Villani C, Bendini AV, et al.: Young Age is not an Ominous Prognostic Factor in Breast Cancer Patients. *Tumori* 1987;73: 233
367. Muss HB, Kute TE, Vase LD, et al : The relationship of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. *Cancer* 1989;64:1894.
368. Niklason LT, Kopans DB, Hamberg LM. Digital breast imaging: tomosynthesis and digital subtraction mammography. *Breast Dis* 1998, 10 : 151-164
369. O'Reilly SM, Camplejohn RS, Barnes DM et al : Node negative breast cancer: prognostic subgroups defined by tumor size and DNA flow cytometry. *J Clin Oncol* 1998: 2040.
370. Orel S. Who should have breast magnetic resonance imaging evaluation? *J Clin Oncol* 2008, 26 : 703-711
371. Orel SG, Weinstein SP, Schnall MD, et al. MR imaging in patients with axillary node metastases and unknown primary malignancy. *Radiology* 1999, 212 : 543-549

372. Ottesen GL, Graversen HP, Blichert-Toft et al. : Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. *Am J Surg Pathol* 1993 17(1): 14.
373. Ozzello L (1971): Ultrastructure of intra-epithelial carcinomas of the breast. *Cancer* 28: 1508.
374. Page DL and Anderson TJ *Diagnostic Histopathology of the Breast. Carcinoma in situ (CIS):* Churchill Livingstone ed. p 157 1987:
375. Page DL, Dupont WD, Rogers LW and Rados MS Atypical hyper-plastic lesions of the female breast. A long term follow-up study. *Cancer* 1985: 55: 2698.
376. Palmer MK, Lythgoe JP and Alwyn Smiths: Prognostic Factor in Breast Cancer *Br J Surg* 1982;69:697.
377. Parker SH and Jobe WE (1993): Ed. *Percutaneous breast biopsy.* New York Raven Press.
378. Parker SH, Burbank F, Jackman RJ et al. : Percutaneous large-core breast biopsy: a multi-institutional study. *Radiology* 1994;193: 359.
379. Partridge SC, Gibbs JE, Lu Y, et al.. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. *AJR Am J Roentgenol* 2005, 184 : 1774-1781
380. Pascual MR, Rodriguez M, Layas A, et al.: Factors associated with Prognostic in Human Breast Cancer. II. Multivariate Stratification. *Analysis Neoplasm Réf* 1982.
381. Patchefsky AS, Potok J, Hoch WS et al.: Increased detection of occult breast carcinoma after more thorough histologic examination of breast biopsies. *AISP* 1973 60: 799.
382. Peters NH, Borel R, I, Zuithoff NP, et al. Meta-analysis of MR imaging in the diagnosis of breast lesions. *Radiology* 2008, 246 : 116-124
383. Perlet C, Heywang-Kobrunner SH, Heinig A, et al.. Magnetic resonance-guided, vacuum-assisted breast biopsy: results from a European multi-center study of 538 lesions. *Cancer* 2006, 106 : 982-990
384. Pfarl G, Helbich TH, Riedl CC, et al. : Stereotactic 11-gauge vacuum-assisted breast biopsy: a validation study. *AJR Am J Roentgenol* 2002, 179 : 1503-1507
385. Philpotts LE, Hooley RJ, Lee CH. Comparison of automated versus vacuum-assisted biopsy methods for sonographically guided core biopsy of the breast. *AJR Am J Roentgenol* 2003, 180 : 347-351
386. Pilinik S and Leis HPJ : *Clinical Diagnosis of Breast Cancer.* *Cancer* 1977;39: 2709.
387. Pisano ED, Gatsonis C, Hendrick E, et al.: . Diagnostic performance of digital versus film mammography for breast-cancer screening. *N Engl J Med* 2005, 353 : 1773-1783

388. Pisano ED, Hendrick RE, Yaffe M, et al. : Should breast imaging practices convert to digital mammography? A response from members of the DMIST Executive Committee. *Radiology* 2007, 245 : 12-13
389. Pisano ED, Hendrick RE, Yaffe MJ, et al.: Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. *Radiology* 2008, 246 : 376-383
390. Piver M, Jishi M, Tsukada Y et al.: Primary peritoneal carcinoma after prophylactic oophorectomy in women with family history of ovarian cancer. *Cancer* 1993;71: 2751.
391. Pinder SE, Wencyk P, Sibbernig DM, et al.: Assessment of the new proliferation marker MIB 1 in breast carcinoma rising image analysis associations with other prognostic factors and survival. *Br J Cancer* 1995 71: 146.
392. Poggi MM, Danforth DN, Sciuto LC, et al.: Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. *Cancer* 2003, 98 : 697-702
393. Posner JB and Chernik NL (1978): Intracranial metastases from systemic cancer. *Advances in Neurology* 19: 575.
394. Quenel N, Wafflard J, Bonichon F, et al.: The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases *Breast. Cancer Res Treat* 1995;35: 283
395. Rapin R, Contesso G, Mouriesse et al.: Medullary breast carcinoma re-evaluation of 95 cases of breast cancer with inflammatory stroma *Cancer* 1988 61: 2503.
396. Rapport du Haut Comite de la Santé Publique (1995): Contrôle de qualité anatomocytopathologiste. *Cancer du sein. Arch Anat Cytol Path* 43: 101.
397. Rawling G, Arriagada R, Fontaine F, et al. : Plexite brachiale post radiotherapie. Expérience de l'Institut Gustave-Roussy. Masson. Réf (1983):
398. Raza S, Baum JK. Solid breast lesions: evaluation with power Doppler US. *Radiology* 1997, 203 : 164-168
399. Raza S, Chikarmane SA, Nielsen SS, et al.: . BI-RADS 3, 4, and 5 lesions: value of US in management--follow-up and outcome. *Radiology* 2008, 248 : 773-781
400. Rayter Z Steroid receptors in breast cancer *Br J Surg* 1991: 78: 528.
401. Rebner M and Raju C Non invasive breast cancer. *Radiology* 1994: 190:623.

402. Rimesten A, Stenkuist B, Johanson H, et al. The diagnostic accuracy of palpation and fine needle biopsy and an evaluation of their combined use in the Diseases of the Breast Lesions. Report on a prospective study in 1244 women with symptoms. *Ann Surg* 1975; 182 (1): 1.
403. Rosai J (1991): Borderline Epithelial Lesions of the Breast. *Am J Surg Pathol* 14:209.
404. Rosen PP, Braun DW and Kinne DE: The clinical significance of preinvasive breast carcinoma. *Cancer* 1980 46 (suppl) 919.
405. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. *Radiographics* 2007, 27 Suppl 1 : S215-S229
406. Rosen PP, Grohen S, Kinne DW, et al Factors influencing prognosis in node-negative breast carcinomas: analysis of 767 T1 M0/T2 patients with long-term follow-up. *J Clin Oncol* 1993; 11: 2090.
407. Rosen PP and Kimmel M Occult breast carcinoma presenting with axillary lymph node metastases: A follow-up study of 48 patients. *Human Pathol* 1990: 21: 518.
408. Rosen PP, Lesser MI and Kinne DW Breast Carcinoma at the Ex-tremes of Age: A Comparison of Patients Younger than 35 years and Older than 75 years. *J Surg Oncol* 1985: 28:90.
409. Rosen PP, Lieberman PH, Braun DW, et al.: Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. *Am J Surg Pathol* 19782: 225.
410. Rosner D, Bedwani RN, Vana J, et al.: Non invasive breast carcinoma: results of a national survey by the American College of Surgeons. *Ann Surg* 1979 189: 377 .
411. Rubesova E, Grell AS, De M, V, Metens T, et al. : Quantitative diffusion imaging in breast cancer: a clinical prospective study. *J Magn Reson Imaging* 2006, 24 : 319-324
412. Sacconi-Jotti G, Petit JY and Contesso G : Minimal Breast Cancer: a clinically meaningful term? *Seminars in oncology* 198613: 384.
413. Sakorafas GH, Tsiotou AG, Pavlakis G. Follow-up after primary treatment for breast cancer. *Acta Oncol* 2000, 39 : 935-940
414. Sancho-Gamier H, Lancry PJ and Fagnani F (1991): Economic Evaluation of systematic screening of Breast and cervical cancers, Réf (EEC Report)
415. Sardanelli F, Giuseppetti GM, Panizza P, et al.: Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard. *AJR Am J Roentgenol* 2004, 183 : 1149-1157
416. Saslow D, Boetes C, Burke et al. : American Cancer Society guide-lines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin* 2007, 57 : 75-89

417. Schnitt SJ, Wang HH and Tavassoli FA: Interobserver reproducibility in the diagnosis of ductal proliferative lesions using standardization criteria. *Am J Surg Pathol* 1992;16: 1133.
418. Schorn C, Fischer U, Luftner-Nagel S, et al. MRI of the breast in patients with metastatic disease of unknown primary. *Eur Radiol* 1999, 9 : 470-473
419. Schorn C, Fischer U, Luftner-Nagel S, et al. Diagnostic potential of ultrafast contrast-enhanced MRI of the breast in hypervascularized lesions: are there advantages in comparison with standard dynamic MRI? *J Comput Assist Tomogr* 1999, 23 : 118-122
420. Schwartz GF, Feig SA and Patchefsky AS (1978): Clinicopathologic correlations and significance of clinically occult mammary lesions. *Cancer* 41: 1147
421. Schwartz LH, Koerner FC, Edgerton SM, et al.: pS2 expression and response to hormonal therapy in patients with advanced breast cancer. *Cancer Res* 1991;51:624
422. Schwartz GF, Patchefsky AS, Feig SA, et al. Multicentricity of non palpable breast cancer. *Cancer* 1980; 45 (12): 29.
423. Senn BE, Dupont L, V, Oelschlegel C, Senn HJ. Multitarget stereo-tactic core-needle breast biopsy (MSBB)--an effective and safe diagnostic intervention for non-palpable breast lesions: a large prospective single institution study. *Breast* 2006, 15 : 339-346
424. Shaw de Parades E: Atlas of film-screen mammography 2nd ed. Baltimore, 1992 Williams and Wilkins.
425. Shen WC, Chang RF, Moon WK. Computer aided classification system for breast ultrasound based on Breast Imaging Reporting and Data System (BI-RADS). *Ultrasound Med Biol* 2007, 33 : 1688-1698
426. Sickles EA: Breast masses: mammographic evaluation. *Radiology* 1989;173: 297.
427. Sickles EA, Philpotts LE, Parkinson BT, et al. : Imaging curriculum for resident and fellow education in breast imaging. *J Am Coll Radiol* 2006, 3 : 879-884
428. Sigal-Zafrani B, Muller K, El Khoury C. Vacuum-assisted large-core needle biopsy (VLNB) improves the management of patients with breast microcalcifications - analysis of 1009 cases. *Eur J Surg Oncol*. 2008; 34(4):377-81.
429. Sigurdson H, Baldetorp B and Borg A et al: Indicators of prognosis in node negative breast cancer. *N Eng J Med* 1990 322: 1045.
430. Siiteri PK: Review on studies of estrogen biosynthesis in the human. *Cancer Res*. 1982 42 (suppl): 3269s.

431. Silverberg SG, Kay S, Chitale AR, et al.: Colloid carcinoma of the breast. *Am J Clin Pathol* 1971 55: 355.
432. Silverstein MJ, Pollet DN, Waisman JR, et al.: Prognostic Classification of breast ductal carcinoma in situ. *Lancet* 1995 345: 1154
433. Silvestrini R, Benini E, Daidotie MG, Veneroni S, Boracchi P, Cap-pelletti V, Di Fronzo G and Veronesi U (1993): p53 as an Diagnostic marker in lymph node negative breast cancer patients. *J Natl Cancer Inst* 85: 965
434. Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Salvadori B and Veronesi U (1995): Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancers. *J Clin Oncol* 13 : 697.
435. Sinha SP, Goodsitt MM, Roubidoux MA, Booi RC, LeCarpentier GL, Lashbrook CR, Thomenius KE, Chalek CL, Carson PL. Automated ultra-sound scanning on a dual-modality breast imaging system: coverage and motion issues and solutions. *J Ultrasound Med* 2007, 26 : 645-655
436. Singletary SE, Allred C, Ashley P, et al.: Revision of the American Joint Committee on Cancer staging system for breast cancer. *J Clin Oncol* 20 (17): 3628-36, 2002. [PUBMED Abstract]
437. Singletary SE, Greene FL, Sobin L: Classification of Isolated Tumor Cells. *Cancer* 2003: 2740-42.
438. Skaane P, Diekmann F, Balleyguier C, et al. Observer variability in screen-film mammography versus full-field digital mammography with soft-copy reading. *Eur Radiol* 2008, 18 : 1134-1143
439. Skaane P, Hofvind S, Skjennald A. Randomized trial of screen-film versus full-field digital mammography with soft-copy reading in population-based screening program: follow-up and final results of Oslo II study. *Radiology* 2007, 244 : 708-717
440. Skjennald A. Novel techniques in breast imaging: evaluation of diagnostic efficacy. *Acta Radiol* 2005, 46 : 773
441. Slamon DJ, Clark GH and Noug SG (1987): Amplification of the Her-2/neu oncogene correlates with relapse in survival in human breast cancer. *Science* 235: 177.
442. Sorensen S, Borgesen SE, Rohde K et al. (1990): Metastatic epidural spinal cord compression. Results of treatment and survival. *Cancer* 65: 1502.
443. Spyrtatos F, Hacene K, Tubiana-Hulni M, et al.: Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1262 patients. *Eur Cancer Clin Oncol* 1989 25: 1233.
444. Spyrtatos F, Martin PM, Hacene K, et al.: Multiparametric prognostic evaluation of biological factors in primary breast cancer. *J Natl Cancer Inst* 1992 84: 1266.

445. Spyrtos F, Maudelonde T, Brouillet JP, et al.: Cathepsin D: An in-dependent prognostic factor for metastasis of breast cancer. *Lancet* 1989 8672:1115.
446. svsssjvStal O, Wnigren S, Cortensen J et al (1989): Prognostic value of DNA ploidy and S phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer. *Eur J Cancer Clin Oncol* 25: 301.
447. Stanwell P, Mountford C. In vivo proton MR spectroscopy of the breast. *Radiographics* 2007, 27 Suppl 1 : S253-S266
448. Stavros AT and Dennis MA (1993): The ultrasound of breast pathol-ogy. In Parker SH, Jobe WE Ed. *Percutaneous breast biopsy*. New York, Ra-ven Press.
449. Stavros AT, Thickman D, Rapp CL, Dennis MA, Parker SH, Sisney GA. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. *Radiology* 1995, 196 : 123-134
450. Steeg PS, De la Rosa A, Flatow U, MacDonald NJ, Benedict M and Lecone A (1993): nm23 and breast cancer metastasis. *Breast Cancer Res Treat* 25: 175.
451. Steintal CF (1905): Zur Dauertheilung des Brustkrebses Betir-2, *Klin Chir* 47:226.
452. Stewart JL, Ruben RD and Millis RR et al. (1983): Steroid receptor and prognosis in operable (stage I and II) breast cancer. *Eur J Cancer Clin Oncol* 19:1381.
453. Stomper PC, Recht A, Berenberg AL et al. (1987): Mammographic detection of recurrent cancer in the irradiated breast. *A J R* 148: 39.
454. Sugarbaker PH, Beard JO and Drum DK (1977) Detection of Hepatic Metastases from cancer of the Breast. *Ann. J Surg* 133:531.
455. Suissa M, Levy L, Bokobsa J, Martin B, Chiche JF, Teman G. Sur-veillance du sein traité. *Imagerie Femme* 2008, 2006 : 237-249
456. Swayampakula AK, Dillis C, Abraham J. Role of MRI in screening, diagnosis and management of breast cancer. *Expert Rev Anticancer Ther* 2008, 8 : 811-817
457. Tabar L and Dean P (1985): Teaching atlas of mammography. Stug-gart: G Thieme.
458. Tabar L and Haus AG (1989): Processing of mammographic films: technical and clinical considerations. *Radiology* 173: 65.
459. Tabar L, Dean PB and Penteck Z (1983): Galactography: the diag-nostic procedure of choice for nipple discharge. *Radiology* 149: 31.
460. Tabar L, Duffy SW, Burhenne LD (1993): New Swedish breast can-cer detection: results for women aged 40-49. *Cancer* 72(4): 1437.

461. Tabar L, Fagerberg G and Duffy S W et al. (1989): The Swedish two-country trial of mammographic screening for breast cancer. Recent results and calculation of benefit. *J Epidemiol Community Health* 43: 107.
462. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mam-mography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. *Lancet* 2003, 361 : 1405-1410
463. Taieb S, Ceugnart L. [Breast MR imaging: validated indications and unsolved problems]. *Bull Cancer* 2008, 95 : 147-152
464. Taieb S, Ceugnart L, Rocourt N: L'imagerie dans la surveillance des seins traités. In : Grumbach Y, et al. (eds): *La prise en charge des cancers du sein : l'implication du radiologue*. SOFMIS, Nancy, Palais des congrès, 22-24 mai 2008. Nancy, Bialec, 2008, pp 65-70
465. Taiëb S, Ceugnart L. Plaidoyer pour une utilisation raisonnée de l'IRM dans le dépistage du cancer du sein. *Imagerie Femme* 2003, 16 : 229-213
466. Tardivon A, El Khoury C, Thibault F, Wyler A, Barreau B, Neuenschwander S. [Elastography of the breast: a prospective study of 122 lesions]. *J Radiol* 2007, 88 : 657-662
467. Tardivon A. [How to follow-up women with dense breasts by imaging?]. *J Radiol* 2008, 89 : 1204-1208
468. Tardivon A, Malhaire C, El Khoury C, et al.: Bilan d'un cancer du sein avant traitement : IRM pour toutes ? In : Grumbach Y, et al. (eds): *La prise en charge des cancers du sein : l'implication du radiologue*, SOFMIS, Nancy, Palais des congrès, 22-24 mai. Nancy, 2008, pp 29-33
469. Tardivon AA, Athanasiou A, Thibault F, El Khoury C. Breast imaging and reporting data system (BIRADS) magnetic resonance imaging illustrated cases. *Eur J Radiol* 2007, 61 : 216-223
470. Tardivon AA, Athanasiou A, Thibault F, El Khoury C. Breast imaging and reporting data system (BIRADS): magnetic resonance imaging. *Eur J Radiol* 2007, 61 : 212-215
471. Thibault F, Hagay C, Boyer B. [Breast imaging]. *J Radiol* 2004, 85 : 942-950
472. Thompson M, Jensen R, Obermiller P et al. (1995): Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. *Nature Genet* 9: 444.
473. Thono E, Cosgrove DO and Sloane JP (1994): Scanning techniques. In Thono E, Cosgrove DO and Sloane JP Ed. *Ultrasound diagnosis of breast diseases*. PIT New York, Churchill Livingstone.
474. Toikkanen S, Helin H, Isola J and Ioensuu H (1992): Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. *J Clin Oncol* 10: 1044

475. Toikkanen S, Joensuu H, and Klempner P (1989): The prognostic significance of nuclear DNA content in invasive breast cancer - a study with long-term follow-up. *Br J Cancer* 60: 693.
476. Troufleau P, Chevrier-Fraboulet B, Noel A, Stines J. [Breast imaging]. *J Radiol* 2005, 86 : 848-858
477. Tubiana M, Pejovic MH, Koscielny S, Chavaudra N, and Malaise E (1989): Growth rate kinetics of tumor cell proliferation and long-term outcome in human breast cancer. *Int J Cancer* 44: 17
478. UICC (1988): TNM Classification of malignant tumors. 4eme ed., Springer Verlag ed; p 100.
479. Usami S, Moriya T, Kasajima A, Suzuki A, Ishida T, Sasano H, Ohuchi N. Pathological aspects of core needle biopsy for non-palpable breast lesions. *Breast Cancer* 2005, 12 : 272-
480. Van Dongen JA, Holland R and Peterse JL (1992): Ductal carcinoma in situ of the breast; second EORTC Consensus meeting. *Eur J Cancer* 28: 626.
481. Van Zee KJ. Breast imaging: a breast surgeon's perspective. *Radiol Clin North Am* 2002, 40 : 517-520
482. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. *N Engl J Med* 2002, 347 : 1227-1232
483. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R and Chassagne J (1991): Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinomas. *Natl Cancer Inst* 83: 111
484. Wallis M, Tardivon A, Helbich T, Schreer I. Guidelines from the European Society of Breast Imaging for diagnostic interventional breast procedures. *Eur Radiol* 2007, 17 : 581-588
485. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. *JAMA* 2004, 292 : 1317-1325
486. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. *Ann Intern Med* 2008, 148 : 671-679
487. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S and Gasparini G (1992): Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. *J Natl Cancer Inst* 84: 1875.
488. West JP (1965): Carcinoma of the breast. Results of radical mastectomy. *NY State J Med* 65: 245.

489. Witkowski R, Economou SG, Metegran OV, Petasnick JP and Southwick HW (1978): Compound Tomography of the Abdomen as an aid to preoperative Diagnosis. *Am J Surg* 135:776.
490. Wilkinson LS, Given-Wilson R, Hall T, Potts H, Sharma AK, Smith E. Increasing the diagnosis of multifocal primary breast cancer by the use of bilateral whole-breast ultrasound. *Clin Radiol* 2005, 60 : 573-578
491. Wittliff JL (1987): Steroid Hormone receptors. In: *Methods in Clinical Chemistry*. Pesce and Kaplan (eds.) C. V. Mosby. USA 767.
492. Wittliff JL, Lewko WM and Park DC et al. (1978): Steroid binding proteins of mammary tissues and their clinical significance in breast cancer. In: *Hormones, Receptors, and Breast Cancer*. McGuire (edt.). Raven, USA: 325.
493. Witzig TE, Ingle JN, Schaid DJ, Wold LE, Barlow JF, Gonchoroff NJ, Gerstner JB, Krook JE, Grant CS, and Katzmann JA (1993): DNA ploidy and percent S Phase as prognostic factors in node-positive breast cancer results from patients enrolled in two prospective randomized trials. *J Clin Oncol* 11: 351.
494. Wood CBB, Beek PE and Blumgart LH (1978): Biochemistry Assessment for hepatic Metastasis. *Clinical Oncology* 1:106.
495. Woodhams R, Matsunaga K, Iwabuchi K, Kan S, Hata H, Kuranami M, Watanabe M, Hayakawa K. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. *J Comput Assist Tomogr* 2005, 29 : 644-649
496. Woodward WA, Strom EA, Tucker SL, et al.: Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. *J Clin Oncol* 21 (17): 3244-8, 2003. [PUBMED Ab-stract]
497. World Health Organization (WHO) (1988): Histologic typing of breast tumor. 2nd International Histologic Classification of Tumors, No 2. Geneva, World Health Organization, p. 19.
498. Zackrisson S., Andersonni., Janzon L. et al. Rate of over diagnosis of breast cancer 15 years after and of Malmö mammographic screening trial : follow up sudy. *BMJ* 2006, 332: 689-91.
499. Zafrani B, Vielh P, Fourquet A, Mosseri V, Durand JC, Salmon RJ, Vilcoq JR (1989): Conservative treatment of early breast cancer Prognostic value of the ductal in situ component and other pathological variables on lo-cal control and survival Long-term results. *Eur J Cancer Clin Oncol* 25: 1645
500. Zonderland HM, Pope TL, Jr., Nieborg AJ. The positive predictive value of the breast imaging reporting and data system (BI-RADS) as a me-thod of quality assessment in breast imaging in a hospital population. *Eur Radiol* 2004, 14 : 1743-1750

501. Amar S., Roy V., Perez E. A., Treatment of metastatic breast cancer : looking towards for the future Breast Cancer Res. Treat. 2008
502. American College of Surgeons: Commission on Cancer (1979): Final Report on Long Term Patients Care Evaluation Study for the Female Breast. P.1.
- 503 Baum M (1976): The curability of breast cancer. Br Med J 1: 439.
504. Bedwani T, Vana J, Rosner D, Schmitz RL and Murphy GP (1981): Management and survival of female patients with "minimal" breast cancer: as observed in the long-term and short-term surveys of the American College of Surgeons. Cancer 47: 2769.
- 505 Brinkley D and Haybittle JL (1971): Treatment of stage III carcinoma of the female breast. Lancet 2: 1086.
506. Denoix P (1970): Treatment of malignant breast tumors. In: Recent Results in Cancer Research. Vol. 31, Berlin, Springer Verlag.
- 507.. Goldhirsch A, Food WC, Senn HJ, Glick JH and Geber RD (1995): Commentary, Meeting high lights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl. Cancer Inst 87, 19: 1441.
508. Henderson LC and Harris JR (1991): Principles in the management of metastatic disease. In: Harris LR, Hellman S, Henderson LC, Kinne D (eds). Breast diseases, 2nd ed. Lippincott, Philadelphia, p 547.
509. Hortobagui GN, Piccart Gebhart MJ (1996): Current management of advanced breast cancer. Semi Oncol 23: Suppl 11:1-5.
510. Letton AH and Mason EM (1980): The treatment of non palpable cancer of the breast. Cancer 46: 980.
- 511.. Levene MB, Harris JR and Hellman S (1971): Treatment of carcino-ma of the breast. Cancer 39: 2840.
512. Lippman M (2000): Editorial: high-dose chemotherapy plus autolog-ous bone marrow transplantation for metastatic breast cancer. N Engl J Med 15:1119
513. National Institute of Health Consensus Conference (1991): Statement on the treatment of early stage breast cancer Oncology (Hunchingt). 5:120
514. Peto J, Collins N, Barfoot R, et al. (1999): The prevalence of BRCA1 and BRCA2 mutations among early onset breast cancer cases in the UK. J Natl Cancer Inst 91:943-49

- 515 Peto R, Pike MC, Armitage P et al. (1976-1977): Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. *Br J Cancer* 34: 353. II. Analysis and examples *Br J Cancer*. 35.
516. Schottenfeld D, Nash AG, Robbins GF and Beattie E (1976): Ten-year results of the treatment of primary operable breast carcinoma. *Cancer* 38: 1001.
- 517 Valagussa P, Brambilla, C and Zambett M (1989): Salvage treatments in
518. Aihara T, Munakata S, Morino H, Takatsuka Y. Feasibility of senti-nel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study. *J Surg Oncol*. 2004 Feb;85(2):77-81.
519. Alderman S (1976): Combination teletherapy and Iridium implantation in locally advanced breast cancer. *Cancer* 38: 1936.
520. Alran S, De Rycke Y, Fourchette V, Charitansky H, Laki F, Falcou MC, Benamor M, Freneaux P, Salmon RJ. The Institut Curie Breast Cancer Study Group (Brigitte Sigal-Zafrani, coordinator). Validation and limitations of use of a Breast Cancer Nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. *Ann Surg Oncol*. 2007 Aug;14(8):2195-201.
521. Amalric R, Santamaria F, Robert F et al. (1982): Radiation therapy with or without primary limited surgery for operable breast cancer. A 20-year experience at the Marseille Cancer Institute. *Cancer* 49: 30.
522. Almaric R, Samamaria F and Robert F et al. (1983): Conservative therapy of operable breast cancer. Results at five, ten and fifteen years in 2216 consecutive cases. In Harris JR, Hellman S and Silen W, Eds. *Conservative Management of Breast Cancer*. Philadelphia, J. B. Lippincott 15.
523. Arnez Z, Bajec J, Bardsley A, Scamp T and Webster M (1991): Experience with 50 free TRAM flap breast reconstructions. *Plast Reconstr Surg* 87(3): 470.
524. Arnaud S, Houvenaeghel G, Guiramand J, et al : Patients' and surgeons' perspectives on axillary surgery for breast cancer. *Eur J Surg Oncol* 30:735-743, 2004.
525. Arriagada R, Mouriesse H, Sarrazin D, Clark RM and Deboer G (1985): Radiotherapy alone in breast cancer. 1. Analysis of tumor parameters, tumor dose and local control: The Gustave - Roussy Institute and Princess Margaret Hospital. *Int J Radiat Oncol Biol Phys* 11: 1751.
- 526 Ascherman J.A., Hanasono M M, Newman M I, et al : Implant Re-construction in Breast Cancer, in Patients Treated with Radiation Therapy.
527. *Plast Reconstr Surg* 2006; 117(2): 359- 365
528. Atkins H et al. (1972): Treatment of early breast cancer, a report after ten years of clinical trial. *BMJ* 12:423.

529. Awwad HK and El-Badawy SA (1972): Radiotherapy in the management of operable breast cancer. *The Medical Journal of Cairo University* 40: 35.
530. Baclesse F (1948): La Roentgentherapie sein dans le traitement des cancer du sein operables et inoperables. Rapport au 51 Congres de Chirurgie, Paris.
531. Baclesse F (1965): Five-year results in 431 breast cancer treated sole-ly by roentgen rays. *Annals of Surgery* 103.
532. Baclesse F, Ennuyer A and Cheguillaume J (1960): Est-on autorise a pratiquer une tumorectomie simple suivie de radiothérapie en cas de tumeur mammaire? *J Radiol Electrol* 41: 137.
533. Baclesse F, Gricouroff G and Taillefer A (1939): Essai de Roentgen-therapie du cancer du sein suivi d'opération large. Résultats histologiques. *Bull Cancer* 28: 729.
534. Baclesse F, Nezelof C and Vilde F (1969): Association cobaltothérapie - chirurgie *Eur J Cancer* 5: 219.
535. Bartelink H, Van Dam F, and Van Dongen J (1985): Psychological effects of breast conserving therapy in comparison with radical mastectomy. *Int J Radiat Oncol Biol Phys* 11: 381.
536. Bedwani T, Vana J, Rosner D, Schmitz RL and Murphy GP (1981): Management and survival of female patients with "minimal" breast cancer: as observed in the long-term and short-term surveys of the American College of Surgeons. *Cancer* 47: 2769.
537. Berg JW. The significance of axillary node levels in the study of breast carcinoma. *Cancer*, 1955, 8:776-8.
538. Bleiweiss IJ, Chadandeeep SN, Jaffer S: Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. *J Clin Oncol* 2006;24:2013-2018.
539. Boyages J, Recht A, Connolly JL, Schnitt SI, Gelman R, Kooy H, Love S, Osteen RT, Cady B, Silver B and Harris JR (1990): Early breast cancer: predictors of breast recurrence for patients treated with conservative surgery and radiation therapy. *Radiother Oncol* 19: 29.
540. Burkhardt B and Denias C (1994): The effect of siltex texturing and povidone iodine irrigation on capsular contracture around saline inflatable breast implants. *Plast Reconstr Surg* 93(1): 123.
541. Calle R (1973): Principes d'irradiation. Extraits de Thérapeutiques non mutilantes des cancers du Sein p. 83, Masson Ed.
542. Calle R, Fletcher GH and Pierquin B (1973): Les bases de la radio-thérapie curative des épithéliomas mammaires. *J Radiol Electrol* 54: 929.

- 543 Calle R, Pilleron J, Schlienger P and Vilcoq J (1978): Conservative management of operable breast cancer: ten years experience at the Foundation Curie. *Cancer* 42(4): 2045.
- 544 Calle R, Vilcoq JR, Pilleron JP, Schlienger P and Durand JC (1983): Conservative treatment of operable breast Carcinoma by irradiation with or without limited surgery, ten-year results. In Harris JR, Hellman S and Silen W. Eds. *Conservative Management of Breast Cancer*, Philadelphia, J. B. Lippincott, 3.
- 545 Cascino TL (1991): Radiation myelopathy. In: Rottenberg DA (ed). *Neurological complications of cancer treatment*. Butterworth-Heinemann, Boston, 69.
- 546 Chagpar A., Langstein H.N., Kronowitz S.J., et al. Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction *Am J Surg* 187 (2004) 164–169
- 547 Chapgar A, Middleton L, Sahin et Al. Clinical outcome of patients with lymph node-negative breast carcinoma who have SLN micrometastases detected by immunohistochemistry. *Cancer* 2005;103:1581-6.
- 548 Colleoni M, Rotmensz N, Peruzzotti G et Al. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. *J Clin Oncol* 2005; 23: 1379-1389
- 549 Clough KB, Heitz D, Salmon RJ. Chirurgie loco-régionale des cancers du sein. *Encycl Méd Chir (Elsevier SAS, Paris, tous droits réservés), Techniques chirurgicales – Gynécologie*, 41-970, 2003, 15p.
550. Cothier-Savey I, Rimareix F, Belichard C Principes généraux de la chirurgie oncoplastique et de la reconstruction mammaire immédiate et différée *Encyclopédies Médico chirurgicales , techniques chirurgicales : chirurgie plastique, reconstructrice et esthétique* 45-664, 2002, 14p
- 551 Chu FCH, Lin FJ, Kin JH, Hub SH and Garmatis CI (1976): Locally recurrent carcinoma of the breast. Results of radiation therapy. *Cancer* 37: 2677.
- 552 Clark RM (1953): Alternatives to mastectomy - The Princess Margaret Hospital Experience. In Harris JR, Hellman S and Silen W Eds. *Conservative Management of Breast Cancer*, Philadelphia, J. B. Lippincott, 33.
- 553 Clarke D and Mansel R (2001): Sentinel node biopsy in breast cancer. *EJSO* 27(1): 4-8.
- 554 Coleman DJ, Foo ITH and Sharpe DT (1991): Textured or smooth implants for breast augmentation? A prospective controlled trial. *British Journal of Plastic Surgery* 44: 444.
- 555 Connolly JL and Schnitt SJ (1988): Evaluation of breast biopsy specimens in patients considered for treatment by conservative surgery and radiation therapy for early breast cancer. *Path Ann. (Part I)*: 1.
- 556 Culliton HJ (1977): Cancer Institute Unilaterally Issues New Restrictions on Mammography. *Science* 169:443.

- 557 Dao T, Rahmouni A, Campana F et al. (1993): Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced imaging. *Radiology* 187: 751.
- 558 Deore SM et al (1993): Influence of Dose-rate and dose per fraction on clinical outcome of breast cancer treated by external beam irradiation plus iridium-192 implants: Analysis of 289 cases. *Int J Radiation Oncol Biol Phys* Vol. 26: 601.
- 559 Deore SM, Sarin R, Dinshaw KA and Shrivastava SK (1993): Influence of dose rate and dose per fraction on clinical outcome of breast cancer treated by external beam irradiation plus iridium-192 implants: analysis of 289 cases. *Int J Radiat Oncol Biol Phys* 26: 601.
- 560 Dowlatshahi K, Fan M, Snider H, Habib F. Lymph node micrometastases from breast carcinoma. *Cancer* 1997; 80:1188-97.
561. Downes K.J., Glatt B. S., Kanchwala S. K., et al Skin-Sparing Mastectomy and Immediate Reconstruction Is an Acceptable Treatment Option for Patients with High-Risk Breast Carcinoma. *Cancer* 2005;103:906–13.
- 562 Elliott L, Eskenazi L, Beegle P et al. (1993): Immediate TRAM flap breast reconstruction: 128 consecutive cases. *Plast Reconstr Surg* 92(2):217.
- 563 Fisher B, Barren M, Margolese R et al. (1980): Five years results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without, radiation in the treatment of breast cancer. *N Engl J Med* 312: 665
- 564 Fischer B, Slack NH, Cavanaugh PJ et al. (1970): Post-operative radiotherapy in the treatment of breast cancer. *Ann Surg* 172: 711.
- 565 Fisher B, Bauer M, Margolese R, Poisson R, Pilch T, Redmond C, Fisher E, Wolmark N, Deutsch M, Montague E, Saffer E, Wickerham L, Lerner H, Glass A, Shibata H, Deckers P, Ketcham A, Oischi R and Russell I (1985): Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. *N Engl J Med* 312: 655.
- 566 Fontaine F, Sarrazin D, Rosenwald YC and Grelor D (1977): Amélioration technique et dosimétrique d'une irradiation du cancer du sein. *Ann. Radiol* Vol. XX, p. 185.
- 567 Fourquet A, Campana F, Mosseri V, Cetingoz R, Luciani S, Labib A, Asselain B, and Vilcoq J R (1995): Iridium-192 versus cobalt-60 boost in 3-7 cm breast cancer treated by irradiation alone: final results of a randomized trial. *Radiother Oncol* 34: 114.
- 568 Freneaux P, Nos C, Vincent-Salomon A et Al. Histological detection of minimal metastatic involvement in axillary sentinel nodes : a rational basis for a sensitive methodology usable in daily practice. *Mod Pathol* 2002;15:641-646.

- 569 Galimberti V. International Breast Cancer Study Group (IBCSG)- Trial 23-01. Phase iii randomized study of surgical resection with or without axillary lymph node dissection in women with clinically node-negative breast cancer with sentinel node micrometastasis; 2004 [Available from: <http://cancer.gov/clinicaltrials/IBCSG-23-01>].
570. Gerbault A et al (1995): Brachytherapy in the Management of breast cancer: A Review Institut Gustave Roussy.
- 571 Giuliano A. American College of surgeons Oncology Group. ACOZOG-Z0011. A randomized trial of axillary node dissection in women with clinical T1 or T2 N0 M0 breast cancer who have a positive sentinel node;2004. [available from:http://www.acosog.org/studies/organ_site/breast/index.jsp]
- 572 Giuliano AE, Kirgan DM, Guenther JM et al : Lymphatic mapping and sentinel lymphadenectomy for breast cancer. *Ann Surg* 220:391-398, 1994.
- 573 Green FL, Page DL, Fleming ID et al. : AJCC Cancer staging Manuel(ed 6). New York, NY, Springer,2002.
- 574 Grossman F. Uber die axillaren lymphdrusen:Inaugural dissertation. 1896, Berlin, Germany.
575. Groupe d'étude des cancers du sein de l'Institut Curie (Brigitte Sigal-Zafrani, coordinatrice). Institut Curie- Référentiels de traitement des cancers du sein- Mise à Jour 2005.
576. Gunman R (1963): Radiotherapy in the treatment of operable carci-noma of the breast with proved lymph node metastases. *Ann. Roentgenol* 89: 58.
577. Gylbert L, Asplund O and Jurrel G (1990): Capsular contracture after breast reconstruction with silicone gel and saline filled implants: a six-years follow-up. *Plast Reconstr Surg* 85(3): 373.
578. Haigh PI, Hansen NM, Qi K , et al: Biopsy method excisionvolume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer. *Ann Surg Oncol* 2000; 7:21-27.
579. Hall P (1991): Cancer risks after medical radiation. *Med. Oncol. Tumor Pharmacother* 8: 141.
580. Halsted WS (1894/95): The results of operations for the cure of can-cer of the breast performed at the John Hopkins Hospital from June 1889 to July 1894, *John Hopkins Hosp Bull.* 4: 297.
581. Halsted WS. The results of radical operations for the cure of carci-noma of the breast. *Ann Surg* 1907;46:1-10
582. Hamilton T, Longlands AO and Prescott RT (1974): The treatment of operable cancer of the breast: A clinical trial in the south-east region of Scot-land. *Br J Surg.* 61:758.
583. Hammerstein GR, Miller DAV and White DR et al. (1979): Absorbed radiation dose in mammography. *Radiology* 130: 483.

584. Handley RS (1969): A Surgeon's view of the spread of breast cancer. *Cancer* 24: 1231.
585. Harris JR and Hellman S (1953): The results of primary radiation therapy for early breast cancer at the Joint Centre for Radiation Therapy. In Harris JR, Hellman S and Silen W. Eds. *Conservative Management of Breast Cancer*, Philadelphia, J. B. Lippincott, 47.
586. Harris JR, Hellman S and Silen W (1983): Conservative management of breast cancer. *New Surgical and Radiotherapeutic Techniques*, Philadelphia, J. B. Lippincott Co.
587. Harris JR, Recht A, Almaric R, et al. (1984): Time course and prognosis of local recurrence, following primary radiation therapy for early breast cancer. *J Clin Oncol* 2: 37.
588. Harris JR, Sawicka J, Gelman R and Hellman S (1983): Management of locally advanced carcinoma of the breast by primary radiation therapy. *Int J Radiat Oncol Biol Phys* 9: 345.
589. Hery M, Maner M, Verschoove J, Monticelli J, Boublil JL and La-lanne CM (1984): Conservative treatment of breast cancer: A report on 108 patients. *Int J Radiat Oncol Biol Phys* 21: 55.
590. Holland R, Connolly IL, Gelman R, Mravunac M, Hendriks JHCL, Verbeek ALM, Schnitt SJ, Silver B, Boyages J and Harris JR (1990): The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. *J Clin Oncol* 8: 113.
591. Host H and Brenhovd IO (1977): Does post-operative radiation have any place following radical mastectomy? *Int J Radiol Oncol Biol Phys* 2: 1061.
592. Host H and Brenhovd O (1977): The effect postoperative radiotherapy in breast cancer. *Int J Radiat Oncol Biol Phys* 2: 1061.
593. Koe S and Johansen H (1968): Simple versus radical mastectomy in primary breast cancer. In *Prognostic Factors in Breast Cancer*, E. & S. Livingstone Ltd., Edinburgh, p. 93.
594. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of sentinel lymph node in breast cancer using a gamma probe. *Surg Oncol* 1993;2;335-340.
595. Kronowitz S.J., Feledy J.A., Hunt K. K., M.D., et al Determining the Optimal Approach to Breast Reconstruction after Partial Mastectomy. *Plast. Reconstr. Surg.* 117: 1, 2006.
596. Kurtz JM, Jacquemier J, Almaric R, Brandone H, Ayme Y, Hans D, Bressac C, Roth J and Spitalier JM (1990): Risk factors of breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapy *Cancer* 65: 1867.
597. Kurtz JM, Spitalier JM and Almaric R (1983): Late breast recurrence after lumpectomy and irradiation. In *J Radiat Oncol Biol Phys* 9: 1191.
598. Kuske RR (1995): Breast brachytherapy LDR & HDR. International brachytherapy programme and abstracts 8th International Brachytherapy Conference p 61

- 599 Lacour J, Le M et al. (1983): Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten-year results of an international cooperative trial in breast cancer. *Cancer* 51: 1941.
600. Lacour J, Le M, Petit JY, Contesso G and Sarrazin D (1977): Mastectomie radicale et modifiée dans le traitement du cancer du sein. *Bull Cancer* 64: 393.
601. Langer I, Marti RM, Guller U et Al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node or SLN micrometastases. *Annals of Surgery* 2005;241:15 2-158.
602. Lee Y-TN (1984): Surgical Treatment of Carcinoma of the Breast: III. Pathological Findings and Probability of Relapse. *J Surg Oncol* 25: 109.
- 603 Lyman GH, Giuliano E Somerfield MR et Al. American Society of Clinical Oncology Guideline Recommendations for Snetinel Lymph Node Bi-opsy in Early-Stage Breast Cancer. *J Clin Oncol* 23:7703-7720.
- 604 Madden JI, Kandalaft S, Bouraque RA. Modified mastectomy. *Ann Surg* . 1972; 175:624-34.
605. Malata CM and Sharpe DT (1992): On the safety of Breast implants. *The Breast* 1: 62.
606. Mamounas EP, Brown A, Anderson A et al.: Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. *J Clin Oncol* 2005; 23:264-2702.
- 607 Mansel R. After Mapping of the Axilla: Radiotherapy or Surgery AMAROS: EORTC 10981-22023. [Available from: <http://www.ncrn.org.uk/portfolio/data.asp?ID=1424>]
- 608 Mansel RE, Fallowfield L, Kissin et al.: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. *J Natl Cancer Inst* 2006;98:599-609.
- 609 Mazzeron JJ (1995): New strategies breast cancer (stage I and stage II) HDR LDR Brachytherapy. French Experience. Centre des tumeurs Group hospitalier Pitié-salpêtrière, Paris
- 610 Missana M.C, Barreau Pouher L, Janin N Radiotherapy and immediate breast reconstruction with myocutaneous flap in breast cancer of re-served prognosis *Ann Chir Plast Esthet* 2000 Apr ; 45(2) : 83-89
- 611 Montague ED, Schell SR, Romsdahl MM and Ames FC (1983): Con-servative surgery and irradiation in clinically favorable breast cancer - The MD Anderson experience. In Harris JR, Hellman S, Silen W. Eds, *Conservative Management of Breast Cancer*, Philadelphia, JB Lippincott, 53.
- 612 Noone RB, Murphy JB, Spear SL and Little IJW (1985): A 6-year experience with immediate reconstruction after mastectomy for cancer. *Plast Reconstr Surg* 76(2): 258.

- 613 Nos C, Freneaux P, Guilbert S, Falcou MC, Salmon RJ, Clough KB. Sentinel lymph node detection for breast cancer: which patients are best suited for the patent blue dye only method of identification? *Ann Surg Oncol.* 2001;8(5):438-43.
- 614 Orton CG and Ellis F (1973): A simplification in the use of the NSD concept in practical radiotherapy. *Brit J Radiol* 46: 529.
- 615 Patey DH, Dyson WH. The prognosis of carcinoma of the breast in relation to the type of operation performed. *Br J Cancer* 1948;2:7-13.
- 616 Paterson R and Russel H (1959): Clinical trials in malignant disease. Part III Breast Cancer. Evaluation of post operative radiotherapy. *Clin Radiol* 10: 179.
- 617 Petit JY (1991): *Cancer du sein. Chirurgie diagnostique, curative et reconstructrice.* MEDS1 McGRAW-HILL ed: p 105.
- 618 Petit JY, Le MG, Mouriessse H. et al. (1994): Can breast reconstruction with gel filled silicone implants increase the risk of death and second primary cancer in patients treated by mastectomy for breast cancer? *Plastic and Reconstr Surg* 94(1): 115.
- 619 Petit J and Rietjens M (1991): Deformities following tumorectomy and partial mastectomy. In: Noone B (ed.) *Plastic and reconstructive surgery of the breast.* Philadelphia: B.C. Decker Inc.
620. Petit JY, Veronesi U, Orecchia R, et al Nipple-sparing mastectomy in association with intra operative radiotherapy (ELIOT): A new type of mastectomy for breast cancer treatment. *Breast Cancer Res Treat* 2006 Mar;96(1):47-51. 27.
- 621 Pierquin B (1953): Conservative treatment for carcinoma of the breast: Experience of Creteil, ten-year results. In Harris JR, Helinann S, and Silen W. Eds. *Conservative management of breast cancer.* Philadelphia, J. B. Lippincott 11.
- 622 Pierquin B, Owen R, Maylin C, Otmezguine Y, Raynal M, Mueller W and Hannoun S (1979): Radical radiation therapy of breast cancer. *Int J Radiat Oncol Biol Phys* 5: 17.
623. Pierquin B, Wilson JF and Chassagne D (1987): *Female Breast in: Modern brachytherapy.* Masson Publishing USA.
- 624 Pocard M, Pouillart P, Asselain B, Salmon RJ: Hepatic resection in metastatic breast cancer : results and prognostic factors. *Eur. J. Surg. Oncol.*, 2000, 26, 155-159.
625. Purushotham AD, Upponi S, Klevesath MB et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a random-ized controlled trial. *J Clin Oncol.* 2005 Jul 1;23(19):4312-21.
- 626 Rainsbury R.M., Skin-sparing mastectomy *British Journal of Surgery* 2006; 93: 276–281

- 627 Rawlings G, Arriagada R, Fontaine F, Bouhnik H, Mouriessse H. and Sarrazin D (1983): Plexite brachiale post-radiotherapique: Experience de L'Institute Gustave-Roussy. Bull Cancer (Paris) 70:77.
- 628 Recht A, Silver B, Schmitt S, Connoly J, Hellman S and Harris JR (1955): Breast relapse following primary radiation therapy for early breast cancer. I. Classification, frequency and salvage. Int J Radiat Oncol Biol Phys 11: 1211.
- 629 Recht A, Triedman SA and Harris JR (1991): The boost in the treatment of early stage breast cancer, Electrons versus interstitial implants. Front Radiat Ther Oncol 25: 169
- 630 Recommendations pour la pratique clinique de Saint-Paul-deVence. Oncologie 2005 ;7 :342-379.
- 631 Rotter J: Zur topographie des Mamma-carcinoma. Arch Klinische Chirurgie 1899;58:346-356.
- 632 Salmon RJ, Ansquer Y, Asselain B. Preservation versus section of in-tercostal-brachial nerve (IBN) in axillary dissection for breast cancer--a pro-spective randomized trial. Eur Surg Oncol 1998; 24 :158-61.
- 633 Salmon RJ, Nos C, Lojodice F, Languille O, Remvikos Y, Vilcoq JR, Clough KB. Sentinel node and operable breast cancer: utilization of blue dye injection. Pilot study. Ann Chir. 2000;125(3):253-8.
- 634 Sappey C. PH. Anatomie, physiologie, pathologie des Vaisseaux Lymphatiques Adrien Delahaye Librairie Editeur paris 1874.
- 635 Sarrazin F (1988): La radiothérapie des cancers du sein. R Prat Tome XVIII n°25/35373548.
636. Sarrazin D, Dewar JA Arriagada R, Benhamou S et al. (1988): Con-servative management of breast cancer: 797 patients treated at the Institut Gustave Roussy. Brit J Surg
637. Sarrazin D, Fontaine MF et al. (1983): Conservative treatment versus mastectomy in T1 or small T2 breast cancer: a randomized trial. In: Harris JR ed. Conservative management of breast cancer. Philadelphia: J. B. Lippincott, 101.
- 638 Sarrazin D, Le M, Rouesse J et al. (1984): Conservative Treatment versus Mastectomy in Breast Cancer Tumors with Macroscopic Diameter of 20 millimeters or less. The experience of Institute Gustavo Roussy. Cancer 53: 1209
- 639 Sarrazin D, Le M, Rouesse J et al. (1984): Conservative treatment versus mastectomy in breast cancer tumors with macroscopic diameter of 20 millimeters or less. Cancer 33: 12-9.
- 640 Sarrazin D, Le MG, Arriagada R, Contesso G, Fontaine F, Spielman M, Rochar F, Le Chevalier TH and Lacour J (1989): Ten year results of ran-domized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 14:177
- 641 Sarrazin D, Tubiana M, Le M, Fontaine F and Aarriagada R (1980): Conservative treatment of minimal breast cancer. Breast Cancer, p. 251. Edited by Mouridsen et Nalshof Pergamon Press. Oxford. New York.

- 642 Schechter, N.R. MD,* Strom E.A., H.Perkins G.H., et al , Immediate Breast Reconstruction can Impact Postmastectomy Irradiation Am J Clin Oncol 2005;28: 485–494
643. Sergott TJ, Limoli JP, Baldwin CM and Laub DR (1986): Human ad-juvant disease, possible autoimmune disease after silicone implantation: a re-view of the literature, case studies, and speculation for the future. Hum Adj Dis 78: 104.
644. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, and Kitchen P (1993): Clinical significance of HER-2/neu oncogene amplification in primary breast cancers. Clin Oncol 11: 1936.
645. Smitt MC, Nowels KW, Zdeblick MJ, Jeffrey S, Carlson RW, Stock-dale FE and Goffinet DR (1995): The importance of the lumpectomy surgical margin status in long term results of breast conservation. Cancer 76: 259.
646. Stevens PE, Dibble SL and Miaskowski C (1995): Prevalence, characteristics and impact of postmastectomy pain syndrome: An investigation of women's experiences. Pain 61: 61.
647. Stjernsward J (1974): Decreased survival related to irradiation post-operatively, in early operable breast cancer. Lancet 2: 1285.
648. Tailhefer A. Pronostic et traitement chirurgical et radiochirurgical des cancer du sein. Ann Chir. 1961 ;15 :403-15 .
649. Tavassoli FA (1993): Pathology of the breast. Chapter 3, p 64. Ap-pleton & Lane, Norwalk, Connecticut Thoma, A, Veltri K., Khuthaila D., et al, Comparison of the Deep Inferior Epigastric Perforator Flap and Free Transverse Rectus Abdominis Myocutaneous Flap in Postmastectomy Reconstruction: A Cost-Effectiveness Analysis Plast Rconst Surg 2004; 113(6): 1650-1661
- 650 Trojani M, De Mascarel I, Bonichon F, Conidre JM, and Delsol G (1987): The immunohistochemical detection of axillary metastases in invasive breast cancer Prognosis and significance. Br J Cancer 55: 303.
651. Tubiana M and Sarrazin D (1980): A reappraisal of radiotherapy in the treatment of operable breast cancer. The new light on the internal mammary chain role. Breast Cancer p. 243. Pergamon Press.
- 652 Urban JA and Marjani MA (1871): Significance of internal mammary lymph node metastases in breast cancer. Am J Roentgenol Radium Ther Nucl Med 3:130
653. Urban J (1981): Surgical Treatment of Primary Breast Cancer, Edited Lewison E, Montague A. Conservative versus radical Diagnosis and Treatment of Breast Cancer. Williams and Wilkins, Baltimore, London.
654. relapsing resectable breast cancer. Recent Results Cancer Res 115:69.

- 655 Valgussa P, Tancini G, Bonadonna G (1998): Salvage treatment of patients suffering relapse after adjuvant chemotherapy. *Cancer* 58: 1411
656. Vallagussa P, Bonadonna G and Veronesi U (1978): Patterns of re-lapse and survival following radical mastectomy. *Cancers* 41: 110. Van Zee KJ, Manasseh D, Bevilacqua J, Boolboi S, Fey J, Tan L, Borgen P, Cody H, Kattan M. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel lymph node biopsy. *Annals of Surg Oncol* 2003; 10:1140-1151.
- 657 Veronesi U, Paganelli G, Galimberti V et al. Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. *Lancet* 1997; 349: 1864-7.
- 658 Veronesi U and Valagussa P (1981): Inefficacy of internal mammary nodes dissection in breast cancer surgery. *Cancer* 4-1: 170.
- 659 Veronesi U, Saccozzi, Del Vecchio et Al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. *N Engl J Med* 1981; 305:6-11.
660. Veronesi U, Salvadori B et al. (1990): Conservative treatment of early breast cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection and radiotherapy. *Ann of Surgery* 211(3): 250.
- 661 Vilcoq JR. Et Al. the outcome of treatment by tumorectomy and radiotherapy of patients with operable breast cancer. *Int J Radiat Oncol Biol Phys* 1981;7: 1327-32.
662. Vrdoljak DV, Ramjolak V, Muzina D et al.: Analysis of metastatic involvement of interpectoral (Rotter's) lymph nodes related to tumor location, size, grade and hormone receptor status in breast cancer. *Tumori* 2005;91(2):177-81.
- 663 Wallgreen A, Amer O, Bergstrom J, Blomsteat B, Ray C and Silfersward C (1978): Preoperative radiotherapy in operable breast cancer. Results in the Stockholm Breast Cancer Trial. *Cancer* 42: 1120.
664. Zafrani B, Vielh P, Fourquet A, Mosseri V, Durand JC, Salmon RJ, Vilcoq JR (1989): Conservative treatment of early breast cancer Prognostic value of the ductal in situ component and other pathological variables on local control and survival Long-term results. *Eur J Cancer Clin Oncol* 25: 1645
665. Zoetmulder FAN et al (1993): Breast conserving therapy in patients with relatively large (T2, T3) breast cancers by preoperative irradiation and myocutaneous LD flap reconstruction. A new technique in breast conservation *Eur J Cancer*. Vol. 29A No 7: 957.
666. Albain K, Barlow W, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100) (abstract 10). Program and abstracts of the 30th Annual San Antonio Breast Cancer Symposium, Dec 13-16, 2007.

- 667 Allegra JC, Lippman ME and Thompson EB (1978): An Association between steroid hormone receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. *Cancer Treat. Rep.* 62: 1281.
668. Antman KH, Rowlings PA, Vaughan WP et al. (1997): High dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. *J Clin Oncol* 18:70-9.
669. Amman S, Armitage JO and Horwitz, MM (1994): Autotransplants for breast cancer in North America. *Pro Am Soc Clin Oncol* 13: 66 Abst. 69.
670. Andersen T, Heimdal K, Skrede M et al. (1994): Estrogen receptor (ESR) polymorphisms and breast cancer susceptibility. *Hum Genet* 66:5.
- 671 Baldini E, Gardin G., Gianesi PG et al : Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil : a randomized phase III in locally advanced breast cancer. *Ann Oncol* 14: 227-3é 2003
- 672 Banning A, Sjogren P and Henriksen H (1991): Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. *Pain* 45: 45.
673. Baum M and Benson LR (1995): Current and future roles of adjuvant endocrine therapy in the management of early carcinoma of the breast. In: *Adjuvant Therapy of Breast Cancer*. V. Senn, Gelber, Goldhirsch, Thurlimann (eds). Springer, Germany, 215.
674. Beatson GT (1896): On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method-of treatment with illustrative cases. *Lancet* ii: 104, 162.
675. Bitran VD, Desser RK, Shapiro CM, Michel A, Knzloff MT, Billins AA and Recent W (F-83) Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy. *Cancer* 51: 381.
676. Blackstein M, Vogel CL, Aminder R et al. (1997): Phase II study of gemcitabine in patients with metastatic breast cancer. *Eur J Cancer* 33: S 149 (Suppl 8, abstract 664).
677. Bonadonna G and Valagtlssa P (1981): Dose response effect of adjuvant chemotherapy in breast cancer. *New J.*
678. Brain E, Misset JL, Rouëssé J. Primary chemotherapy or hormonal therapy for patients with breast cancer. *Cancer Treat Rev*, 1999, 25 : 187-197.
679. Buckner VC, Ingle JN and Everson IK (1989) Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer. *Breast Ca Res Treat* 13: 135.

680. Brunner KW, Sanntng RW, Martz G et al. (1975): A controlled study in the use of combined drug therapy for metastatic breast cancer. *Cancer*, 36: 1208.
- 681 Bull JM, Tormey DC et al. (1978): A randomized comparative trial of adriamycin versus methotrexate in Combination drug therapy. *Cancer* 41: 1649.
- 682 Cancer Research Campaign Working Party (King's Cambridge) (1980): Trial for early breast cancer. A detailed update at the tenth year. *Lan-cet* ii: 55.
- 683 Canellos GP, Popcock SJ, Sears ME and Klaassen DJ (1976): Com-bination chemotherapy for metastatic breast carcinoma, prospective comparison of multiple drug therapy with L-phenylalanine mustard. *Cancer* 36: 1882.
- 684 Canellos GP, Popcock SJ, Taylor SG et al. (1976): Combination chemotherapy for metastatic breast carcinoma: Prospective comparison of multiple drug therapy with L-phenylalanine mustard. *Cancer* 38: 1882.
- 685 Carbone PP and Davis TE (1978): Medical treatment of advanced breast cancer. *Semin Oncol* 5, 417.
686. Carter SK (1976): Chemotherapy of breast cancer: Current studies, 193-215, In Henson, JC and Mattheiem WH, (eds.): *Breast Cancer. Trends in Research and Treatment*, N.Y., Raven Press.
- 687 Chapko MK, Syrjala KL, Schilter L, Cummings C and Sullivan KM (1990): Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea. *Bone Marrow Transplantation* 4: 181.
- 688 Chauvergene J, Durand M, Buivin Brunet (1980): Chemotherapies des cancers mammaires par une association de mitomycin C, Thiotepa et Vendisene. *Bordeaux Med* 13/14, 686.
- 689 Citron MI, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent com-bination chemotherapy as operative adjuvant treatment of node-positive pri-mary breast cancer : first report of Intergroup Trial C9741: Cancer and Leu-kemia Group B trial 9741 *J Clin Oncol* 21 : 1431-9 2003
- 690 Coates AS, Keshaviaz A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for post menopausal women with endocrine-responsive early breast cancer : update od study BIG 1-98 *J Clin Oncol* 2007; é(: 486-92
- 691 Collaborative Group on Hormonal Factors in Breast Cancer (1996): Breast cancer and hormonal collaborative reanalysis of individual data on 53,297 with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. *Lancet* 347:1713-27.

- 692 Coombs DW (1990): Pain due to liver capsular distention. In: Fewer-Brechner T (ed) Common problems in pain management. Common problems in anesthesia. Year Book Medical Publishers, Chicago, 247.
- 693 Coombs RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years'tamoxifen treatment (Intergroup Exemestane Study) : a randomized controlled trial. *Lancet* 2007; 369: 559-70.
- 694 Cooper RG (1969): Combination chemotherapy in hormone resistant breast cancer, *Proc. Am. Assoc. Cancer Res Am Soc Clin Oncol.* 15: 15 (Ab-stract).
- 695 Curran, CF, Luce JK and Page JA (1990): Doxoatbicin-associated dare reactions. *Oncology Nurses Forum*, 17: 387.
- 696 Davis BOW, Gelber RD, Goldhirsch A, Hartmann H, Locher GW and Reed R (1986): Prognostic Significance of Tumor Grade in Clinical Trials of Adjuvant Therapy for Breast Cancer with Axillary Lymph Node Metastasis. *Cancer* 58(12): 2662.
- 697 De Castro, Meynadier, Zenz. (1991): Regional Opioid analgesia. De-velopments in critical care medicine and anesthesiology, Kluwer Academic Publishers, Dordrecht. 20.
- 698 Devon M, Basbaum AL, Bennett G et al. (1991): Group Report: me-chanisms of neuropathic pain following peripheral injury. In: Basbaum A and Beson JM (eds) Towards a new pharmacotherapy of pain. John Wiley, New York, p 417.
- 699 Donegan WL (1979): *Disease of the Breast*. 2nd Ed., W. B. Saunders Co., Philadelphia.
- 700 Early breast cancer Trialist's collaborative group. (1992): Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy- 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. *Lancet*, 339: 1-15, 71-85.
- 701 Early Breast Cancer Trialist's Collaborative Group (1992): Systemic treatment of early breast cancer by hormonal, cytotoxic or immunotherapy. *Lancet* 339.
- 702 Dixon AR, Jackson L and Nicholson RL (1990): The use of Goserelin (Zoladex) in premenopausal advanced breast cancer. *Br J Cancer* 62: 32.
- 703 Dray A (1994): Tasting the inflammatory soap: the role of peripheral neurons. *Pain Reviews* 1: 153.
- 704 Early Breast Cancer Trialists'Collaborative Group. Effects of chemo-therapy and hormonal threrapy for early brast cancer on recurrence and 15-years survival : an overview of the randomized trials. *Lancet*. 2005 ; 365: 1687-1717.

- 705 Fisher B, Costantino J, Redmond C et al. (1989): A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor-positive tumors. *N Engl J Med* 320: 479.
- 706 Fisher B, Costantino J, Redmond C et al. (1994): Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. *J Natl Cancer Inst* 86: 527.
- 707 Fisher B, Dignam J, Wieand S and Wolmark N (1996): Duration of tamoxifen therapy for primary breast cancer 5 versus 10 years (NSABP-14). *Proc Am Soc Clin Oncol* 15: 113.
- 708 Fisher B, Redmond C, Legault-Poisson S et al. (1990): Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Adjuvant Breast and Bowel Project B-6. *J Clin Oncol* 8: 1005.
- 709 Fisher B, Redmond C and Brown A et al. (1983): Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. *J Clin Oncol* 1: 227.
- 710 Fisher B, Rockette H, Robinoux A. et al. (1994): Effect of preoperative therapy for breast cancer on local-region disease: First report of NSABP -18. *Proc Am Soc Clin Oncol* 13: 64 (Abstr. 57).
- 711 Forbes J, Cuzick J, Buzdar A, et al: ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion (abstract 41). Program and abstracts of the 30th Annual San Antonio Breast Cancer Symposium, Dec 13-16, 2007.
- 712 Fornander T, Rutquist LE, Cedemark B et al. (1989): Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. *Lancet* i: 117.
- 713 Forsyth PA and Posner JB (1993): Headache associated with intracranial neoplasms. In: Olesen J, Tfelt-Hansen P, Welch, KMA (eds). *The headaches*. Raven Press, New York.
- 714 Grant R, Cordon B, Hart I and Teasdale GM (1991): Changes in intracranial CSF volume after lumbar puncture and their relationship to post-LP headache. *Journal of Neurology, Neurosurgery and Psychiatry* 54: 440.
- 715 Gagliardi A and Collins DC (1993): Inhibition of angiogenesis by anti-estrogens. *Cancer Res.* 3: 533.
- 716 Gardin G, Alama A, Rosso R, Campora E, Repetto L, Pronzato P, Merlini L, Naso C, Camoriano A, Meazza R, Barbieri F, Baldini E, Giannessi PG, and Conte PF (1994): Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. *Breast Cancer Res Treat* 32: 311.

- 717 Gelber RD, Cole BF, Goldhirsh A et al. (1996): Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: a meta-analysis of quality-adjusted survival. *Lancet* 347: 1066.
- 718 Geyer C, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. *N Engl J Med* 355:2733-2743, 2006.
- 719 Gianni A, Bergni M, Siena S et al. (1990): Recombinant human granulocyte macrophage colony stimulating factor reduce hematologic toxicity and widens clinical application of high dose cyclophosphamide in breast cancer and non Hodgkin's Lymphoma. *J Clinical Onco* 8: 768.
- 720 Goldhirsch A, Wood, W.C., Gelber R.D., et al Progress and promise : highlights of the international expert consensus on the primary therapy of early breast cancer 2007; *Ann Oncol* 18 1133-1144
- 721 Goss P, Ingle J, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. *N Engl J Med* 349:1793-1802, 2003.
- 722 Greco A and Hainsworth J (1995): One-hour paclitaxel infusion schedule: A phase I-II comparative trial. *Semin Oncol* 22: 3 Supp 6, 118.
- 723 Greenspan EM (1966): Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma. *J. Mt, Sinai Hospital*.
- 724 Hainsworth JD, Andrews MB and Johnston DH (1991): Mitoxantron 5 FU and high dose Leucovorin. *J Clin Oncol* 9: 1731.
- 725 Harris AL, Cantwell BMJ and Sainsbury JR (1986): Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced post-menopausal breast cancer. *Breast Cancer Res Treat* 7:1.
- 726 Henderson IC, Haves F and Gelman, R (1988): Dose response in the treatment of breast cancer, a critical review. *J Clin Onco* 67: 1501.
- 727 Holmes FA, Waler RS and Theriault RL (1991): Phase II trial of Taxol, an active drug in metastatic breast. *Ca J Nat Ca Inst* 83: 1797.
- 728 Hortobagay GN (1990): The importance of dose response in cytotoxic therapy for breast cancer: Advances in breast cancer treatment. Therapeutic strategies in Oncology. Henderson IC and Broden EC (Eds.) *Mediscript London*. pp 47-69.
- 729 Hortobagay GN, Frye D and Buzdar AL (1989): Cardiac toxicity of Doxorubicin administration by continuous intravenous infusion in combination chemotherapy (AC) for metastatic breast carcinoma. *Cancer* 63: 37.

- 730 Howell A, Downey S and Anderson E (1996): New endocrine therapies for breast cancer. *Eur J of Cancer* 32A: 4, 576.
- 731 Jacquillat CL, Baillet M, Weil M et al (1988): Results of a conservative treatment combining chemotherapy, hormonotherapy and external and interstitial irradiation in 98 patients with locally advanced breast cancer. *Cancer* 61: 1977
- 732 Jaiyesimi IA, Buzder AU, Decker DA and Hortobagyi GN (1995): Use of tamoxifen for breast cancer: twenty eight years later. *J Clin Oncol* 13, 2: 513.
- 733 Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. *N Engl J Med* 354:809-820, 2006.
734. Jones S, Savin M, Holmes F, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. *J Clin Oncol* 24:5381-5387, 2006.
- 735 Jordan VC and Morrow M (1994): Should clinicians be concerned about the carcinogenic potential of tamoxifen? *Eur J Cancer* 30A (11): 1714.
- 736 Kaeckle KA (1991): Nerve plexus metastases. *Neurologic Clinics* 9: 857.
- 737 Kahn CE, Messersmith RN and Samuels BL (1989): Brachia plexopathy as a complication of intra-arterial cisplatin. *Cardiac and Interventional Radiology* 12: 47.
- 738 Kamel M and Tawfik MO (1994): Pathogenesis and Prevalence of breast cancer pain in Egypt. *J.E.S.M.P.* 2: 54.
- 739 Kerbart P, Delgado FM, Furmeleau P, et al. (1992): Phase II trial with Vinorelbine in advanced breast cancers. *Proceedings of the 7th NCI-EORTC. Symposium of New Drugs in Cancer Therapy* p 126. Amsterdam.
- 740 Knotts PH, Aisner J, Van Echo DA et al. (1980): Mitomycin and Vinblastin chemotherapy for advanced breast cancer. *Pro Am Assoc Clin Res Am Soc Clin Oncol* 21: 410
- 741 Lacour J, Lacour F, Spira A et al. (1984): Adjuvant treatment with polyadenylic polyuridylic acid in operable breast cancer: Updated results of a randomized trial. *Br Med J* 288: 589.
- 742 Love RR, Majess RB, Borden PD et al. (1992): Effects of tamoxifen on bone mineral density in women with breast cancer. *N. Engl. J. Med.* 326: 852.
- 743 Lucas FV and Perez-Mesa C (1978): Inflammatory carcinoma of the breast. *Cancer* 41: 1595.
- 744 Mathieu MC, Koscielny S, Le Bihan ML, Spielmann M and Arriagada R (1995): p53 protein overexpression and chemosensitivity in breast cancer. *Lancet* 345: 1181

- 745 Mattsson W, Borgstrom S and Landberg T (1982): A weekly schedule of low-dose doxorubicin in treatment of advanced breast cancer. *Clin Ther* 5: 193.
- 746 McQuay HJ (1994): Do pre-emptive treatments provide better pain control? Proceedings of the 7th. World Congress on Pain. Progress in pain research and management, Vol. 2, edited by Gebhart GF, Hammond DL and Jensen TS IASP Press, Seattle, WA, USA. 709. *Med* 304: 10.
- 747 Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab ver-sus paclitaxel alone for metastatic breast cancer. *N Engl J Med* 357:2666-2676, 2006.
- 748 Misset IL, Di Palma M, Delgado M et al. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, Fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration.
- 749 Moiseyenko V, O'Reilly SM, Talbot DC et al. (1998): A randomized phase II study of xeloda (capecitabine) vs. paclitaxel in breast cancer patients failing previous anthracycline therapy. *Ann Oncol* 9:620 (suppl 4).
- 750 Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, and Henderson IC (1994): C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. *N Engl J Med* 330: 1260.
- 751 Namer M, and Khater R (1993): Estrogens. In: Hand Book of Che-motherapy in Clinical Oncology. Cvitkovic, Droz, Armand and Khoun (edts.) Scientific Communication International Ltd, USA 367.
- 752 Ness TJ and Gebhart GE (1990): Visceral pain: a review of experi-mental studies. *Pain* 41: 167.
- 753 Osborne CK. (1999): Tamoxifen in the treatment of breast can-cer. *N Engl J Med* 339:1609.
- 754 Peacock NW, Burris HA, Hainsworth JD et al (1998): Weekly doce-taxel in patients with advanced refractory malignancies: A phase I trial. *Proc Am Soc Clin Oncol* 17:189a (abstract 727).
- 755 Piccart-Gebhart M, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 353:1659-1672, 2005.
- 756 Plotkin D and Waugh WJ (1983): Hypothesis: discontinuous chemo-therapy for advanced breast cancer. *Am J Clin Oncol (CCT)*, 6: 3-5.
- 757 Portenov RK, Duma C and Foley KM (1986): Acute herpetic and posttherapeutic neuralgia: clinical review and current management. *Annals of Neurology* 20: 651.
- 758 Portenoy RK (1991): Issues in the management of neuropathic pain. In: Basbaum A and Besson JM (eds). Towards a new pharmacotherapy of pain. Wiley, New York, p 393.
- 759 Posner JB (1995): Neurologic complications of cancer. Philadelphia: FA Davis.

760. Powles TJ, Hickish TF, Makris A et al. (1995): Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. *J Clin Oncol* 13: 547.
761. Pritchard K, Messersmith H, Elavathil L, et al: HER-2 and topoisomerase II as predictors of response to chemotherapy. *J Clin Oncol* 26:736-744, 2008.
762. Quesada JR, Ralpaz M, Rios A, Kurzrock R and Gutterman JU (1986): Clinical toxicity of interferons in cancer patients: a review. *Journal of Clinical Oncology* 4: 234.
763. Ranson MR, Carmichael J, O'Byrne K et al (1997): Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. *J Clin Oncol* 15:3185-3191.
764. Ready LB (1991): The treatment of post operative pain. In: Bond MR, Charlton LE, Woolf CJ (eds) *Proceedings of the World Congress on Pain. Pain research and clinical management, vol. 4: Elsevier, Amsterdam p. 53.*
765. Redit A, Come SF, Henderson LC et al. (1996): The sequencing of chemotherapy and radiation therapy after conservative surgery for early stage breast cancer. *N Engl J Med* 334: 1356.
766. Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Madgeltnat H and Pouillart P (1989): Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. *J Natl Cancer Inst* 81: 1383.
767. Romond E, Perez E, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med* 353:1673-1684, 2005.
768. Ross D and Whitehead M (1995): Hormonal manipulation and gynecological cancer: the tamoxifen dilemma. *Current opinion in Obstetrics and Gynecology*. 7, 1: 63.
769. Rouëssé J, Arriagada R, Le Chevalier T, Sevin D, Spielmann M, Amiel JL, Mouriesse H, Sarrazin D, Caille P and May Levin F (1984): Chemotherapy-radiotherapy and hormonotherapy (C.R.H.) in the treatment of 134 inflammatory breast cancers (I.B.C.). *Proc Am Soc Clin Oncol* 3: C-440.
770. Rutquist LE (1993): long term toxicity of tamoxifen. Recent results. *Cancer Res* 127: 257.
771. Schabel FM (1975): Animal models as predictive systems. *Ca Chemotherapy fundamental concepts and recent advances*. 19th Annual Clinical Conf on Cancer. University of Texas, MD Anderson Hospital. Texas USA 1974 Chicago Year Book. Medical Publisher: 323.
772. Schiller JH, Storer B and Tutschk (1994): Phase I trial of 3 hour infusion of Paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer, *J Clin Oncol* 12: 241.
773. Scottish Cancer Trial Office (MRO) (1987): Adjuvant Tamoxifen in the management of operable breast cancer: the Scottish trial. *Lancet* ii: 171.

- 774 Scholl SM, Fourquet A, Asselain B et al. (1994): Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomized trial. *S6. Eur J Cancer.* 30A: 645.
- 775 Schneider PG, Jackisch C and Brandt B (1994): Endocrine management of breast cancer. *International Journal of Fertility and Menopausal Studies*, 39 (suppl.2): 115.
- 776 Seidman A, Reichman B, Crown J et al. (1992): Activity of taxol with recombinant granulocyte colony-stimulating factor as first chemotherapy of patients with metastatic breast cancer. *Proc Am Soc Clin Oncol Abst.* 59.
- 777 Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study (abstract 1). *Breast Cancer Res Treat* 94(suppl 1):S5, 2005.
778. Slamon D, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. *N Engl J Med* 344:783-792, 2001.
- 779 Slamon D, Mackey J, Robert N, et al: Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: Efficacy analyses determined by molecular subtypes of the disease (abstract 13). *Program and abstracts of the 30th Annual San Antonio Breast Cancer Symposium*, Dec 13-16, 2007.
- 780 Sledge G and Amman K (1992): Progress in chemotherapy for metastatic breast cancer. *Semin Oncol* 19: 317.
- 781 Sunderland MD and Osborne CK (1991): Tamoxifen in premenopausal patients with metastatic breast cancer: A review. *J. Clin Oncol.* 9:1283.
- 782 Swedish Breast Cancer Cooperative Group. (1996): Randomized trial of 2 versus 5 years of adjuvant tamoxifen in postmenopausal early-stage breast cancer. *Proc Am Soc Clin Oncol* 15: 126.
- 783 Tapley ND, Spanson WJ Jr., Fletcher GH, Montague ED, Schell S and Oswald MJ (1982): Results in patients with 110 adjuvant chemotherapy. *Cancer* 49: 1316.
- 784 Taylor SG, and Gelber R (1982): Experience of the ECOG with adriamycin as a single agent in patients with previously untreated breast carcinoma. *Cancer Treat. Rep.* 66: 159. 4.
- 785 Therasse P., Mauriac L., Wielnicka-Jaskiewicz et al : Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin and 5-fluorouracil with a dose intensified epirubicin and cyclophosphamide + filgrastin as neoadjuvant treatment of locally advanced breast cancer. *J Clin Oncol* 21 : 843-50 2003

- 786 Tormey DC, Gelman R and Falkson G (1983): Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial. *Am J Clin Oncol (CCT)* 6: 3.
- 787 Tormey DC, Gelman R, Band PR et al. (1983): Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. *Cancer*. 50: 1235.
- 788 Tranum B, Hoogstraten B, Kennedy A et al. (1978): Adriamycin in combination for the treatment of breast cancer. A South-West Oncology Group Study. *Cancer*. 14: 2078.
- 789 Vahdar L, Antman KH (1995): Dose intensive therapy in breast cancer. In: Armitage JO, Antman KH, eds. *High-dose cancer therapy: pharmacology, hematopoietins, and stem cells*. 2nd ed. Baltimore: William & Wilkins pp: 802-23.
- 790 Winer E, Hudis C, Burstein H, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. *J Clin Oncol* 23:619-629, 2005.
- 791 Wood WC, Budman DR, Korzun AH et al. (1994): Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. *N Engl J Med* 330: 1253.
- 792 Young OE, Renshaw L, Macaskill EJ et al :Effects of fulvestrant in premenopausal women with oestrogen –receptor – positive primary breast cancer.*Eur J Cancer* 44 (3) : 391-9. 2008